var title_f19_47_20208="Patient information: Nerve damage caused by diabetes (The Basics)";
var content_f19_47_20208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Nerve damage caused by diabetes (The Basics)",
"  </div>",
"  <a href=\"./authors-and-editors/patient-information\">",
"   Written by the doctors and editors at UpToDate",
"  </a>",
"  <br/>",
"  <br/>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 23, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H727895159\">",
"    <span class=\"h1\">",
"     Can diabetes cause nerve damage?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yes. People with diabetes (sometimes called &ldquo;diabetes mellitus&rdquo;) can get nerve damage if they have high blood sugar levels for a long time. Another word for nerve damage is &ldquo;neuropathy.&rdquo;",
"   </p>",
"   <p>",
"    People with diabetes can get different types of nerve damage. This article covers the most common type of nerve damage caused by diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727895166\">",
"    <span class=\"h1\">",
"     What are the symptoms of nerve damage caused by diabetes?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve damage usually affects the toes and feet first. Some people do not feel any symptoms, but other people can have symptoms that include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Numbness or loss of feeling",
"     </li>",
"     <li>",
"      Burning or pain &ndash; Pain is often worse at rest or at night.",
"     </li>",
"     <li>",
"      Tingling",
"     </li>",
"     <li>",
"      Feeling light touches as bothersome or painful",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As nerve damage gets worse, symptoms can move from the feet up the legs. Once people feel symptoms in the middle of their lower legs, they might also start to feel symptoms in their hands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727895173\">",
"    <span class=\"h1\">",
"     Is there a test for nerve damage caused by diabetes?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yes. Your doctor can usually tell if you have nerve damage by talking with you and doing an exam. Sometimes, a doctor will do a test to check how well a person&rsquo;s nerves are working. This test is called &ldquo;electromyography.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727895180\">",
"    <span class=\"h1\">",
"     How does nerve damage lead to problems?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve damage can lead to problems, because it can make people unable to feel pain in their feet.",
"   </p>",
"   <p>",
"    Normally, people feel pain when they get a cut on their foot. The pain tells them that they need to treat their cut so that it can heal. But people with nerve damage might not feel any pain when their feet get hurt. They might not even know that they have a cut, so they might not treat it. Problems that aren&rsquo;t treated right away can get much worse. For example, an untreated cut can get infected and turn into an open sore.",
"   </p>",
"   <p>",
"    Nerve damage can also lead to problems with the bones, muscles, and joints in the feet. Over time, this can cause a person&rsquo;s foot to have an abnormal shape.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727895187\">",
"    <span class=\"h1\">",
"     What can I do to protect my feet and manage my condition?",
"    </span>",
"    &nbsp;&mdash;&nbsp;You can:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Control your blood sugar levels &ndash; Symptoms of pain and burning sometimes get better when blood sugar levels are under control. To better control your blood sugar, your doctor might prescribe another diabetes medicine or recommend that you take your diabetes medicine more often.",
"     </li>",
"     <li>",
"      Take care of your feet &ndash; Taking care of your feet can prevent future problems. It can also prevent a mild problem from turning into a serious one. To protect and take care of your feet, you can:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wear shoes or slippers all the time. Never go barefoot.",
"     </li>",
"     <li>",
"      Trim your toe nails carefully. Cut straight across and file the nail (",
"      <a class=\"graphic graphic_figure graphicRef80053 \" href=\"UTD.htm?41/51/42814\">",
"       figure 1",
"      </a>",
"      ). Do not cut cuticles or pop blisters. Ask your doctor to do any procedures that could involve cutting the skin, such as removing an ingrown toenail.",
"     </li>",
"     <li>",
"      Wash your feet with warm water and soap every day and pat them dry. Put a moisturizing cream or lotion on the tops and bottoms of your feet.",
"     </li>",
"     <li>",
"      Check both feet every day (",
"      <a class=\"graphic graphic_figure graphicRef77032 \" href=\"UTD.htm?28/40/29313\">",
"       figure 2",
"      </a>",
"      ). Look for cuts, blisters, swelling, or redness. Make sure to check all over your feet, including in between your toes. If you cannot see the bottoms of your feet, use a mirror or ask another person to check.",
"     </li>",
"     <li>",
"      Wear socks that are not too tight, and change them every day. Wear shoes that fit well, but are not too tight (",
"      <a class=\"graphic graphic_figure graphicRef79305 \" href=\"UTD.htm?24/41/25245\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Check inside your shoes before you put them on. Make sure there is nothing sharp inside.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727895194\">",
"    <span class=\"h1\">",
"     What other treatment might I have?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some people might have other treatment for symptoms or problems caused by nerve damage. They might have treatment for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain &ndash; Doctors can prescribe different medicines to treat pain that is caused by nerve damage.",
"     </li>",
"     <li>",
"      Foot problems &ndash; Doctors can treat foot problems that occur. There are different treatments, depending on how serious the problem is. For example, a doctor might do one or more of the following to treat an open sore:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clean the sore and remove any dead skin around it",
"     </li>",
"     <li>",
"      Prescribe antibiotic medicines",
"     </li>",
"     <li>",
"      Do surgery to remove a toe or part of the foot",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727895201\">",
"    <span class=\"h1\">",
"     How often should my doctor check my feet?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your doctor should do a complete check of your feet once a year. He or she should also do a quick check of your feet at every visit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727895208\">",
"    <span class=\"h1\">",
"     Can nerve damage be prevented?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yes. If you have diabetes, you can reduce your risk of getting nerve damage by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Keeping your blood sugar levels as close to normal as possible",
"     </li>",
"     <li>",
"      Not smoking",
"     </li>",
"     <li>",
"      Losing weight, if you are overweight",
"     </li>",
"     <li>",
"      Making sure that your high blood pressure and heart disease are treated (if you have these conditions)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727895215\">",
"    <span class=\"h1\">",
"     More on this topic",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"     Patient information: Type 1 diabetes (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"     Patient information: Type 2 diabetes (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=see_link\">",
"     Patient information: Treatment for type 2 diabetes (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"     Patient information: Quitting smoking (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"     Patient information: Weight loss treatments (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?8/42/8867?source=see_link\">",
"     Patient information: Neuropathic pain (The Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=see_link\">",
"     Patient information: Diabetic neuropathy (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=see_link\">",
"     Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"    </a>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15648 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-200.215.4.194-3D64976229-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20208=[""].join("\n");
var outline_f19_47_20208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727895159\">",
"      Can diabetes cause nerve damage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727895166\">",
"      What are the symptoms of nerve damage caused by diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727895173\">",
"      Is there a test for nerve damage caused by diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727895180\">",
"      How does nerve damage lead to problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727895187\">",
"      What can I do to protect my feet and manage my condition?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727895194\">",
"      What other treatment might I have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727895201\">",
"      How often should my doctor check my feet?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727895208\">",
"      Can nerve damage be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H727895215\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   GRAPHICS",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     FIGURES",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/51/42814\" title=\"figure 1\">",
"      Trim toenails PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/40/29313\" title=\"figure 2\">",
"      Foot check diabetes PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/41/25245\" title=\"figure 3\">",
"      Shoe shape PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=related_link\">",
"      Patient information: Diabetic neuropathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=related_link\">",
"      Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/42/8867?source=related_link\">",
"      Patient information: Neuropathic pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=related_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_47_20209="Achilles tendon US exam";
var content_f19_47_20209=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Achilles tendon sonographic technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows proper sonographic technique for examination of the Achilles tendon. The Achilles tendon should be stretched as much as possible by pointing the big toe towards the examination bench.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Bruyn GA, Schmidt WA. Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist. Bohn Stafleu &amp; Van Loghum, 2006. Copyright &copy;2006 Bohn Stafleu &amp; Van Loghum.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20209=[""].join("\n");
var outline_f19_47_20209=null;
var title_f19_47_20210="Patient information: Urinary tract infections in adults (The Basics)";
var content_f19_47_20210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15353\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/59/23474\">",
"         Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/18/32036\">",
"         Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/58/38818\">",
"         Patient information: Urinary tract infections in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Urinary tract infections in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/urinary-tract-infections-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H294739475\">",
"      <span class=\"h1\">",
"       What is the urinary tract?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The urinary tract is the group of organs in the body that handle urine (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"       figure 1",
"      </a>",
"      ). The urinary tract includes the:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Kidneys, two bean-shaped organs that filter the blood to make urine",
"       </li>",
"       <li>",
"        Bladder, a balloon-shaped organ that stores urine",
"       </li>",
"       <li>",
"        Ureters, two tubes that carry urine from the kidneys to the bladder",
"       </li>",
"       <li>",
"        Urethra, the tube that carries urine from the bladder to the outside of the body",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32947102\">",
"      <span class=\"h1\">",
"       What are urinary tract infections?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Urinary tract infections, also called &ldquo;UTIs,&rdquo; are infections that affect either the bladder or the kidneys. Bladder infections are more common than kidney infections. Bladder infections happen when bacteria get into the urethra and travel up into the bladder. Kidney infections happen when the bacteria travel even higher, up into the kidneys. Both bladder and kidney infections are more common in women than men.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H294739489\">",
"      <span class=\"h1\">",
"       What are the symptoms of a bladder infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain or a burning feeling when you urinate",
"       </li>",
"       <li>",
"        The need to urinate often",
"       </li>",
"       <li>",
"        The need to urinate suddenly or in a hurry",
"       </li>",
"       <li>",
"        Blood in the urine",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32947137\">",
"      <span class=\"h1\">",
"       What are the symptoms of a kidney infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of a kidney infection can include the symptoms of a bladder infection, but kidney infections can also cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Back pain",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H294739496\">",
"      <span class=\"h1\">",
"       How do I find out if I have a urinary tract infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse. He or she will probably be able to tell if you have a urinary tract infection just by learning about your symptoms and doing a simple urine test. If your doctor or nurse thinks you might have a kidney infection or is unsure what you have, he or she might also do a more involved urine test to check for bacteria.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H294739503\">",
"      <span class=\"h1\">",
"       How are urinary tract infections treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most urinary tract infections are treated with antibiotic pills. These pills work by killing the germs that cause the infection.",
"     </p>",
"     <p>",
"      If you have a bladder infection, you will probably need to take antibiotics for 3 to 7 days. If you have a kidney infection, you will probably need to take antibiotics for longer&mdash;maybe for up to 2 weeks. If you have a kidney infection, it&rsquo;s also possible you will need to be treated in the hospital.",
"     </p>",
"     <p>",
"      Your symptoms should begin to improve within a day of starting antibiotics. But you should finish all the antibiotic pills you get. Otherwise your infection might come back.",
"     </p>",
"     <p>",
"      If needed, you can also take a medicine to numb your bladder. This medicine eases the pain caused by urinary tract infections. It also reduces the need to urinate.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H294739510\">",
"      <span class=\"h1\">",
"       What if I get bladder infections a lot?",
"      </span>",
"      &nbsp;&mdash;&nbsp;First, check with your doctor or nurse to make sure that you are really having bladder infections. The symptoms of bladder infection can be caused by other things. Your doctor or nurse will want to see if those problems might be causing your symptoms.",
"     </p>",
"     <p>",
"      But if you are really dealing with repeated infections, there are things you can do to keep from getting more infections. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Find a new method of birth control, if you use spermicides (sperm-killing creams). Using spermicides &mdash; especially with a diaphragm &mdash; seems to promote bladder infections in some women.",
"       </li>",
"       <li>",
"        Drink more fluid. There is no proof that this helps, but many doctors suggest doing it. It might help flush out germs, and it does no harm.",
"       </li>",
"       <li>",
"        Urinate right after sex. Some doctors think this helps, because it helps flush out germs that might get into the bladder during sex. There is no proof it works, but it also cannot hurt.",
"       </li>",
"       <li>",
"        Ask your doctor or nurse about vaginal estrogen, if you are a woman who has been through menopause. Vaginal estrogen comes in a cream or a flexible ring that you put into your vagina. It can help prevent bladder infections.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H294739517\">",
"      <span class=\"h1\">",
"       Can cranberry juice or other cranberry products prevent bladder infections?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The studies suggesting that cranberry products prevent bladder infections are not very good. But if you want to try cranberry products for this purpose, there is probably not much harm in doing so. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H294739524\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=see_link\">",
"       Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"       Patient information: Urinary tract infections in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/47/20210?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15353 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-115.25.216.6-67B0166C29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20210=[""].join("\n");
var outline_f19_47_20210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H294739475\">",
"      What is the urinary tract?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32947102\">",
"      What are urinary tract infections?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H294739489\">",
"      What are the symptoms of a bladder infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32947137\">",
"      What are the symptoms of a kidney infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H294739496\">",
"      How do I find out if I have a urinary tract infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H294739503\">",
"      How are urinary tract infections treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H294739510\">",
"      What if I get bladder infections a lot?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H294739517\">",
"      Can cranberry juice or other cranberry products prevent bladder infections?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H294739524\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15353\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=related_link\">",
"      Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=related_link\">",
"      Patient information: Urinary tract infections in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_47_20211="Flat warts PI";
var content_f19_47_20211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Flat warts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note multiple, flesh-colored flat warts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20211=[""].join("\n");
var outline_f19_47_20211=null;
var title_f19_47_20212="Parasternal short axis TTE I";
var content_f19_47_20212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63963%7ECARD%2F64091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63963%7ECARD%2F64091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Parasternal short axis view of aortic valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 171px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal short axis view from a transthoracic echocardiogram shows the noncoronary (NCC), right coronary (RCC) and left coronary (LCC) leaflets of the aortic valve. Also seen are the left atrium (LA), right atrium (RA), tricuspid valve (TV), right ventricle (RV) and pulmonic valve (PV).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the right ventricular (RV) outflow tract view showing the pulmonic valve and the pulmonary artery bifurcation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulmonary artery (PA) bifurcation into the right (RPA) and left (LPA) pulmonary arteries can be seen in the short axis precordial view. Note that in this view the LPA is proximal to the descending aorta (dAo).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Ao: aorta; RVOT: right ventricular outflow tract; pv: pulmonic valve.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20212=[""].join("\n");
var outline_f19_47_20212=null;
var title_f19_47_20213="Light micrograph showing fibronectin glomerulopathy";
var content_f19_47_20213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F86699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F86699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing fibronectin glomerulopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph (400x) of a glomerulus in a patient with fibronectin glomerulopathy.&nbsp;There is glomerular enlargement and minimal cellular proliferation, producing a&nbsp;lobular or clover-like appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20213=[""].join("\n");
var outline_f19_47_20213=null;
var title_f19_47_20214="Absent diastolic flow";
var content_f19_47_20214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Doppler frequency shift waveforms depicting absent end-diastolic flow velocity in the umbilical artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    As noted in the text, this is an ominous sign associated with adverse perinatal outcome. Note that the wall filter (high pass) was set very low (25Hz, upper right corner) in order to prevent any significant loss of the low frequency Doppler shifts thus ensuring against the artifactual appearance of absent end-diastolic velocity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20214=[""].join("\n");
var outline_f19_47_20214=null;
var title_f19_47_20215="Manifestations of and risk factors for aminoglycoside nephrotoxicity";
var content_f19_47_20215=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20215/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20215/contributors\">",
"     Brian S Decker, MD, PharmD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20215/contributors\">",
"     Bruce A Molitoris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20215/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20215/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20215/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20215/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/47/20215/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury is a relatively common complication of therapy with the aminoglycoside antibiotics, with a rise in the plasma creatinine concentration of more than 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44 to 88",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or 50 percent increase in plasma creatinine concentration from baseline occurring in 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aminoglycosides are freely filtered across the glomerulus and then partially taken up by, concentrated in, and produce damage to proximal tubular cells. The renal injury induced by these drugs is related to their preferential accumulation in the renal cortex. After administration, up to 5 to 10 percent of the parenteral dose is retained in the renal cortex where it can achieve concentrations greatly exceeding the concurrent serum concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/4\">",
"     4",
"    </a>",
"    ]. This preferential sequestration of aminoglycosides in proximal tubule cells accounts for the observation that renal failure may become clinically apparent as late as several days after the drug has been discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The manifestations of and risk factors for aminoglycoside nephrotoxicity are reviewed here. Acute tubular necrosis due to ischemia or other insults, and the pathogenesis and potential therapy of aminoglycoside nephrotoxicity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nonoliguric acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury from aminoglycoside exposure typically manifests after five to seven days of therapy. The non-oliguric aspect of the renal failure is secondary to a loss in renal concentrating ability believed to be the result of distal tubular damage.",
"   </p>",
"   <p>",
"    The acute tubular necrosis that occurs from aminoglycoside exposure is rarely severe, with incremental increases in the plasma creatinine that are usually mild (0.5 to 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [44 to 177",
"    <span class=\"nowrap\">",
"     micromol/liter])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/5\">",
"     5",
"    </a>",
"    ]. However, aminoglycosides can result in toxicity, mandating renal replacement therapy in patients who already have CKD. The urine sediment most commonly shows mild proteinuria, hyaline, and granular casts. The fractional excretion of sodium is generally above one percent (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or, for standard units, (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Distal tubular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal nephron segments also can be affected in aminoglycoside nephrotoxicity. The two major manifestations of distal dysfunction are polyuria due to decreased concentrating ability and hypomagnesemia due to enhanced urinary losses (see next section) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. The polyuria is postulated to be secondary to the attenuation in the sensitivity of the collecting-duct epithelium to endogenous antidiuretic hormone in aminoglycoside nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypomagnesemia, hypokalemia, hypocalcemia, and hypophosphatemia are infrequently observed. This is likely secondary to the decrement in proximal tubule transport that occurs during aminoglycoside-induced nephrotoxicity. A Fanconi-like syndrome can occur with glycosuria, aminoaciduria, phosphaturia, and uricosuria. The loss of phosphorus in the urine results in hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/1\">",
"     1",
"    </a>",
"    ]. With aminoglycoside nephrotoxicity, magnesium depletion resulting in hypomagnesemia can lead to secondary hypokalemia and hypocalcemia.",
"   </p>",
"   <p>",
"    Treatment of aminoglycoside-induced magnesium-wasting consists of the administration of oral or intravenous magnesium supplements. However, the efficacy of this oral regimen is limited by the urinary excretion of most of the extra magnesium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link\">",
"     \"Signs and symptoms of magnesium depletion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=see_link\">",
"     \"Evaluation and treatment of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that proximal tubules can regenerate, the usual course of aminoglycoside nephrotoxicity is one of recovery of renal function. The plasma creatinine concentration usually returns to the prior baseline level within 21 days after cessation of therapy. However, resolution of the acute episode may be delayed if the patient remains hypovolemic, septic, or catabolic; in these settings, tubular regeneration cannot occur.",
"   </p>",
"   <p>",
"    Irreversible kidney damage is uncommon with acute aminoglycoside nephrotoxicity. However, it may occur with prolonged therapy, even in low doses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in other forms of reversible acute renal failure suggest that normalization of the plasma creatinine concentration and even the glomerular filtration rate may not reflect complete recovery. Irreversible nephron loss in this setting may be masked by compensatory hyperfiltration in the remaining normal glomeruli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=see_link\">",
"     \"Renal and patient outcomes after acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although a pattern of a non-oliguric acute kidney injury five to seven days after aminoglycoside exposure is suggestive, differentiating aminoglycoside-induced acute kidney injury from other etiologies of acute tubular necrosis can be difficult, given that it often occurs in the setting of significant comorbid conditions, sepsis, and concomitant nephrotoxin exposure. In addition, acute kidney injury is frequently multifactorial, and aminoglycoside nephrotoxicity is only one of its components. An essential initial diagnostic step in the diagnosis of aminoglycoside nephrotoxicity is a careful history with attention to potentially reversible etiologies, such as reduced effective arterial volume or urinary tract obstruction. In addition, a review of all imaging procedures for intravenous contrast exposure and medications for concomitant nephrotoxin use is imperative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several risk factors have been identified that increase the risk of aminoglycoside nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The major risk factors are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolonged duration of therapy",
"     </li>",
"     <li>",
"      Advanced age",
"     </li>",
"     <li>",
"      Comorbid disease",
"     </li>",
"     <li>",
"      Reduced effective arterial volume",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Concomitant medications",
"     </li>",
"     <li>",
"      Elevated plasma drug concentrations",
"     </li>",
"     <li>",
"      Type of aminoglycoside",
"     </li>",
"     <li>",
"      Frequency of dosing",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prolonged duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of renal insufficiency generally requires at least five to seven days of exposure to aminoglycosides in patients with normal hemodynamic status. Prolonged therapy increases the risk that toxic aminoglycoside concentrations will develop and persist in the renal cortex.",
"   </p>",
"   <p>",
"    For any given aminoglycoside, a direct relationship exists between serum concentrations of aminoglycosides, renal cortical concentrations, and nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. Owing to the renal cortical sequestration of aminoglycosides, the risk of aminoglycoside-induced nephrotoxicity is also increased in patients given the drug in repeated courses separated by a few days or weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, renal cortical accumulation is less when aminoglycosides are given as one large daily dose as in once-daily dosing programs because of the saturable nature of the renal cortical uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/30/8679?source=see_link\">",
"     \"Consolidated aminoglycoside dosing with gentamicin and tobramycin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Advanced age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced age has long been held to be an important risk factor in the development of aminoglycoside nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. This increased risk is postulated to be secondary to the impaired capacity for cellular repair and regeneration found in this patient population. In addition, advanced age may result in excessive dosing of aminoglycosides from an overestimation of creatinine clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Comorbid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of comorbid conditions are associated with aminoglycoside induced kidney disease. Diabetes mellitus and leukemia, for example, increase the risk for aminoglycoside nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early studies of aminoglycoside nephrotoxicity reported increased risk of aminoglycoside nephrotoxicity in patients with chronic kidney disease. In these studies, however, aminoglycoside concentrations were not pharmacokinetically adjusted and patients were likely exposed to high serum levels of aminoglycosides with associated nephrotoxicity. Interestingly, subsequent studies showed that patients with higher creatinine clearances were associated with an increased risk of nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/2,11\">",
"     2,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, patients with chronic kidney disease (CKD) are at increased risk for aminoglycoside nephrotoxicity, because the risk of inadvertent over-dosing is greater than in patients with normal renal function. This increased risk is due to the imprecision of our bedside tools in estimating renal function and aminoglycoside dosing. Furthermore, patients with CKD have less renal reserve and an attenuated ability to recover from aminoglycoside nephrotoxicity.",
"   </p>",
"   <p>",
"    Among patients with advanced liver disease, activation of the renin-angiotensin-aldosterone system may play a pathogenetic role in increasing the risk of aminoglycoside nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, obstructive jaundice with a plasma bilirubin concentration above 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (85",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    is associated with an increased risk of aminoglycoside nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/2,16,17\">",
"     2,16,17",
"    </a>",
"    ]. How obstructive jaundice increases the sensitivity to aminoglycoside toxicity is not known, but either bilirubin or endotoxin (which is absorbed because of decreased bile salt entry into the intestinal lumen) may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/17\">",
"     17",
"    </a>",
"    ]. The hypoalbuminemia frequently observed in advanced liver disease is also an independent risk factor for aminoglycoside nephrotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Reduced effective volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced effective volume results in decreased renal perfusion, renal ischemia, and greatly enhances the risk of aminoglycoside nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This can occur in the clinical setting of intravascular volume depletion, heart failure, sepsis, and advanced liver disease. Moreover, renal ischemia appears to accelerate the time course for aminoglycoside nephrotoxicity.",
"   </p>",
"   <p>",
"    Two factors have been postulated to mediate this synergism between the aminoglycoside and renal ischemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The aminoglycoside interferes with cell energetics, thereby increasing the susceptibility to renal injury during an ischemic episode [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/20\">",
"       20",
"      </a>",
"      ]. This synergism is most prominent in the S3 segment of the proximal tubule; this segment is particularly sensitive to ischemic injury secondary to minimal reperfusion resulting in continuing hypoxia to the area.",
"     </li>",
"     <li>",
"      Ischemia alters membrane lipids. In particular, there is enhanced phosphatidylinositol (PI) content in the luminal membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/21\">",
"       21",
"      </a>",
"      ]. This results in increased aminoglycoside binding, uptake, and accumulation in the proximal tubular cells of S1, S2, and S3 segments, since filtered cationic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      binds to PI and other acidic phospholipids and is then internalized by endocytosis. This charge interaction has important implications for the development and possible prevention of aminoglycoside nephrotoxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"       \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to volume depletion, as described above, endotoxin also enhances the nephrotoxicity of the aminoglycosides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/22\">",
"     22",
"    </a>",
"    ]. Although decreased renal perfusion due to renal vasoconstriction may play a contributory role, endotoxin also appears to be associated with enhanced drug accumulation in the tubules. How this occurs is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Concomitant medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of potentially nephrotoxic medications with aminoglycosides places a patient at increased risk for nephrotoxicity. Implicated medications include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , non-steroidal anti-inflammatory (NSAIDs), angiotensin converting enzyme inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/1,2,14,15\">",
"     1,2,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial studies suggested that cephalothin increased the nephrotoxicity of the aminoglycosides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/23\">",
"     23",
"    </a>",
"    ]. However, patients with sepsis or hypotension were excluded. In this limited population, cephalothin did have a potentiating effect, but the renal injury was mild with the plasma creatinine concentration remaining below 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (176",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in almost all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, there seemed to be no increase in toxic effects when all treated patients are included, which more closely simulates the real world [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, it is unclear if the initial results with cephalothin can be extrapolated to any of the other cephalosporin-type drugs. Evidence suggests that this probably does not occur and that the cephalosporins can be safely given in conjunction with an aminoglycoside [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it seems likely that cephalosporins do not have a major effect on aminoglycoside nephrotoxicity, there is suggestive evidence that concurrent administration of a penicillin may actually be protective [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. How this occurs is not known, but decreased tubular uptake of the aminoglycoside may be involved. It must be emphasized, however, that penicillins, particularly carbenicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"     piperacillin",
"    </a>",
"    , and ticarcillin, can physically complex with the aminoglycosides; as a result, these agents cannot be mixed in the same intravenous infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Elevated plasma drug concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful monitoring of plasma levels is an important component of aminoglycoside therapy. Impaired renal function can occur even with perfect control of the plasma level since renal cortical aminoglycoside accumulation increases with time [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, the risk is much greater in patients receiving divided dose aminoglycoside therapy who develop high peak plasma drug levels (&gt;10",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. In addition, elevated trough levels (&gt;2.5",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    have been associated with nephrotoxicity in a once-daily aminoglycoside dosing program of an elderly cohort of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Remarkably, whether an elevated trough or peak level contribute to the increased risk of nephrotoxicity with aminoglycosides is not fully elucidated. In one analysis, no causal relationship could be found between a serum peak or trough aminoglycoside level in several reviewed studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The therapeutic success observed with once daily aminoglycoside programs with their associated supratherapeutic levels certainly casts doubt on whether a peak aminoglycoside level increases nephrotoxic risk in this clinical setting. However, an elevated trough level has been shown to increase the nephrotoxic risk in once daily aminoglycoside programs in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/12\">",
"     12",
"    </a>",
"    ]. Similarly, in another elderly patient cohort, an elevated peak level increased aminoglycoside nephrotoxicity with conventional dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there remains uncertainty about whether peak or trough levels are primarily responsible for nephrotoxicity, serum monitoring of aminoglycosides is beneficial and recommended due to the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The limitations of our bedside estimates of glomerular filtration rates on which we base our aminoglycoside dosing are often imprecise.",
"     </li>",
"     <li>",
"      Monitoring programs ensure that less toxic antibiotics will be selected in patients with contraindications to aminoglycosides.",
"     </li>",
"     <li>",
"      These programs also ensure that appropriate, therapeutic doses of antibiotics are given earlier in a patient's therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several researchers have demonstrated the benefits of pharmacokinetically monitoring aminoglycoside therapy. This is especially important since few patients have a known glomerular filtration rate allowing for appropriate modeling of the pharmacokinetics. Among the benefits cited were fewer instances of nephrotoxicity and treatment failure and shorter hospital stays [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum peak and trough levels should be measured periodically when conventional aminoglycoside dosing is used. Moreover, peak and trough monitoring in conventional dosing is imperative in elderly and obese patients. In contrast, once daily aminoglycoside programs only require a periodic trough level. This trough level is used to determine the timing of the next dose of aminoglycoside. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/30/8679?source=see_link\">",
"     \"Consolidated aminoglycoside dosing with gentamicin and tobramycin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Type of aminoglycoside",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all of the aminoglycosides appear to have the same potential for nephrotoxicity. However, comparing the relative risk of each of the aminoglycosides for nephrotoxicity is problematic due to the variability in the clinical studies regarding the incidence of nephrotoxicity, the use of controls, and the criteria used to define nephrotoxicity.",
"   </p>",
"   <p>",
"    Overall, when prospective comparative trials are compared,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    has the greatest nephrotoxic potential, followed in decreasing order of nephrotoxicity by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    , and netilmicin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/1,26,33\">",
"     1,26,33",
"    </a>",
"    ]. Although amikacin and netilmicin are considered less nephrotoxic than gentamicin and tobramycin, the difference is not considered profound [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/1\">",
"     1",
"    </a>",
"    ]. The relative nephrotoxic risk of a specific aminoglycoside will always depend on patient factors and comorbid disease and the clinical setting in which the aminoglycoside is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Frequency of dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of dosing may also be a risk factor for the development of aminoglycoside nephrotoxicity. This is supported by the favorable clinical data observed with the once daily aminoglycoside dosing programs. In once daily aminoglycoside therapy, a much larger loading dose is given every 24 to 48 hours. The rationale for this approach is to exploit the concentration-dependent bactericidal activity and post-antibiotic effect of aminoglycosides. This approach to aminoglycoside dosing has demonstrated improved clinical efficacy and reduced nephrotoxicity relative to conventional aminoglycoside dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20215/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/30/8679?source=see_link\">",
"     \"Consolidated aminoglycoside dosing with gentamicin and tobramycin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute kidney injury from aminoglycoside exposure typically manifests after five to seven days of therapy. The non-oliguric aspect of the renal failure is secondary to a loss in renal concentrating ability believed to be the result of distal tubular damage. The acute tubular necrosis that occurs from aminoglycoside exposure is rarely severe. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nonoliguric acute kidney injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypomagnesemia, hypokalemia, hypocalcemia, and hypophosphatemia are infrequently observed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Electrolyte abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given that proximal tubules can regenerate, the usual course of aminoglycoside nephrotoxicity is one of recovery of renal function. The plasma creatinine concentration usually returns to the prior baseline level within 21 days after cessation of therapy. However, resolution of the acute episode may be delayed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several risk factors have been identified that increase the risk of aminoglycoside nephrotoxicity. The major risk factors are prolonged duration of therapy, advanced age, comorbid disease, reduced effective arterial volume, sepsis, concomitant medications, elevated plasma drug concentrations, type of aminoglycoside, and frequency of dosing. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/1\">",
"      Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988; 33:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/2\">",
"      Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/3\">",
"      Meyer RD. Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides. Am J Med 1986; 80:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/4\">",
"      Laurent G, Kishore BK, Tulkens PM. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem Pharmacol 1990; 40:2383.",
"     </a>",
"    </li>",
"    <li>",
"     Chambers, HF. Aminoglycosides. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11 edition, Hardman, JG, Limbird, LE, Molinoff, PB, Ruddon, RW, Goodman Gilman, A (Eds), McGraw-Hill, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/6\">",
"      Patel R, Savage A. Symptomatic hypomagnesemia associated with gentamicin therapy. Nephron 1979; 23:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/7\">",
"      Houghton DC, English J, Bennett WM. Chronic tubulointerstitial nephritis and renal insufficiency associated with long-term \"subtherapeutic\" gentamicin. J Lab Clin Med 1988; 112:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/8\">",
"      Schentag JJ, Jusko WJ. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther 1977; 22:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/9\">",
"      Dahlgren JG, Anderson ET, Hewitt WL. Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob Agents Chemother 1975; 8:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/10\">",
"      Prins JM, B&uuml;ller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/11\">",
"      Smith CR, Moore RD, Lietman PS. Studies of risk factors for aminoglycoside nephrotoxicity. Am J Kidney Dis 1986; 8:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/12\">",
"      Raveh D, Kopyt M, Hite Y, et al. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. QJM 2002; 95:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/13\">",
"      Gall&oslash;e AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/14\">",
"      Paterson DL, Robson JM, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med 1998; 13:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/15\">",
"      Bertino JS Jr, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/16\">",
"      Cabrera J, Arroyo V, Ballesta AM, et al. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982; 82:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/17\">",
"      Desai TK, Tsang TK. Aminoglycoside nephrotoxicity in obstructive jaundice. Am J Med 1988; 85:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/18\">",
"      Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/19\">",
"      Ferriols-Lisart R, Al&oacute;s-Almi&ntilde;ana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996; 53:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/20\">",
"      Zager RA. Gentamicin effects on renal ischemia/reperfusion injury. Circ Res 1992; 70:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/21\">",
"      Molitoris BA, Meyer C, Dahl R, Geerdes A. Mechanism of ischemia-enhanced aminoglycoside binding and uptake by proximal tubule cells. Am J Physiol 1993; 264:F907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/22\">",
"      Zager RA. Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycoside and sepsis-associated acute renal failure. Am J Kidney Dis 1992; 20:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/23\">",
"      Wade JC, Smith CR, Petty BG, et al. Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet 1978; 2:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/24\">",
"      English J, Gilbert DN, Kohlhepp S, et al. Attenuation of experimental tobramycin nephrotoxicity by ticarcillin. Antimicrob Agents Chemother 1985; 27:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/25\">",
"      Bennett WM, Wood CA, Houghton DC, Gilbert DN. Modification of experimental aminoglycoside nephrotoxicity. Am J Kidney Dis 1986; 8:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/26\">",
"      Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/27\">",
"      Aronson JK, Reynolds DJ. ABC of monitoring drug therapy. Aminoglycoside antibiotics. BMJ 1992; 305:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/28\">",
"      McCormack JP, Jewesson PJ. A critical reevaluation of the \"therapeutic range\" of aminoglycosides. Clin Infect Dis 1992; 14:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/29\">",
"      Whipple JK, Ausman RK, Franson T, Quebbeman EJ. Effect of individualized pharmacokinetic dosing on patient outcome. Crit Care Med 1991; 19:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/30\">",
"      Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 2003; 114:194.",
"     </a>",
"    </li>",
"    <li>",
"     Destache, CJ, Meyer, SK, Bittner, MJ, Hermann, KG. Impact of clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Mon; 12:419.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/32\">",
"      Burton ME, Ash CL, Hill DP Jr, et al. A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration. Clin Pharmacol Ther 1991; 49:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20215/abstract/33\">",
"      Lerner AM, Reyes MP, Cone LA, et al. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1983; 1:1123.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7214 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20215=[""].join("\n");
var outline_f19_47_20215=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nonoliguric acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Distal tubular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prolonged duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Advanced age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Comorbid disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Reduced effective volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Concomitant medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Elevated plasma drug concentrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Type of aminoglycoside",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Frequency of dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?25/13/25809?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?24/28/25025?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/30/8679?source=related_link\">",
"      Consolidated aminoglycoside dosing with gentamicin and tobramycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=related_link\">",
"      Renal and patient outcomes after acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_47_20216="Malignant (necrotizing) external otitis";
var content_f19_47_20216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignant (necrotizing) external otitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20216/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20216/contributors\">",
"     Jennifer Rubin Grandis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20216/contributors\">",
"     Victor L Yu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20216/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20216/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20216/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20216/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/47/20216/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant (necrotizing) external otitis (also termed malignant otitis externa) is an invasive infection of the external auditory canal and skull base, which typically occurs in elderly patients with diabetes mellitus. Increasing reports of malignant external otitis in patients infected with the human immunodeficiency virus (HIV) implicate a compromised immune system as a predisposing factor in this disease.",
"   </p>",
"   <p>",
"    Pseudomonas aeruginosa is nearly always the responsible organism. The widespread use of oral and topical fluoroquinolones for the treatment of otitis may make the isolation of P. aeruginosa more difficult and has contributed to the emergence of P. aeruginosa resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical features and management of malignant external otitis will be reviewed here. The spectrum of ear and eye infections due to P. aeruginosa and other clinical syndromes caused by this pathogen are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32503?source=see_link&amp;anchor=H12#H12\">",
"     \"Other Pseudomonas aeruginosa infections\", section on 'Ear infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32503?source=see_link&amp;anchor=H2#H2\">",
"     \"Other Pseudomonas aeruginosa infections\", section on 'Eye infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=see_link\">",
"     \"Pseudomonas aeruginosa skin, soft tissue, and bone infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14775?source=see_link\">",
"     \"Pseudomonas aeruginosa bacteremia and endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=see_link\">",
"     \"Pseudomonas aeruginosa pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of external otitis is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly diabetic patients are overwhelmingly the population at risk for malignant external otitis. More than 90 percent of adults with this disease were found to have some form of glucose intolerance in one review [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/1\">",
"     1",
"    </a>",
"    ]. A number of hypotheses have been advanced to explain this predisposition in diabetics including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microangiopathy in the ear canal which might also occur more commonly in elderly individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased pH in diabetic cerumen [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, susceptibility to malignant external otitis has not been correlated with the level of glucose intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, malignant external otitis is a rare disease in children with fewer than 20 cases reported in the literature. Affected children are more likely to be immunocompromised (eg, malignancy or malnutrition). Children tend to develop fever and leukocytosis in association with this infection, and are more likely than adults to have a concomitant P. aeruginosa bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several reports of malignant external otitis in patients infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. In seven such cases, none of the patients were diabetic and were adults younger than classic patients with this infection.",
"   </p>",
"   <p>",
"    Recent ear surgery and hearing aid irritation may be risk factors for malignant otitis externa [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant external otitis is caused by P. aeruginosa in more than 95 percent of cases. When more than one organism is recovered, isolates accompanying P. aeruginosa tend to be normal skin flora. Occasional reports of cases caused by other organisms have included Aspergillus species [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/14,16-21\">",
"     14,16-21",
"    </a>",
"    ], Staphylococcus aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/22\">",
"     22",
"    </a>",
"    ], Proteus mirabilis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/23\">",
"     23",
"    </a>",
"    ], Klebsiella oxytoca [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/24\">",
"     24",
"    </a>",
"    ], Burkholderia cepacia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/25\">",
"     25",
"    </a>",
"    ], and Candida parapsilosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/26\">",
"     26",
"    </a>",
"    ]. Infection with these other organisms characteristically occurs in immunocompromised hosts, such as those with AIDS or cancer. Among seven cases reported in HIV-infected patients; for example, Aspergillus fumigatus was isolated in three. While most cases of fungal malignant external otitis are due to Aspergillus, other fungi have also been reported, including Scedosporium apiospermum, Pseudallescheria boydii, Candida ciferri, and Malassezia sympodialis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa is a ubiquitous gram-negative bacterium that is capable of growing in distilled water [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Since it is not a normal component of ear canal flora even in diabetic patients, its recovery indicates the presence of a pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27145?source=see_link\">",
"     \"Epidemiology and pathogenesis of Pseudomonas aeruginosa infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contamination of water with Pseudomonas has been directly linked to simple external otitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]. We previously reported a case-control study designed to test the hypothesis that aural water exposure contributed to the development of malignant external otitis. In this study, patients with the disease had a statistically more frequent antecedent history of ear irrigation (generally for the purposes of removing cerumen) compared with matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/35\">",
"     35",
"    </a>",
"    ]. Many reports have subsequently confirmed this association between aural water exposure and malignant external otitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/4,36-40\">",
"     4,36-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with malignant external otitis classically present with exquisite otalgia and otorrhea, which are not responsive to topical measures used to treat simple external otitis. The pain is generally more severe than that found in simple external otitis, although the two may be difficult to distinguish in their early stages. The pain in malignant external otitis tends to be nocturnal and extend into the temporomandibular joint, resulting in pain with chewing.",
"   </p>",
"   <p>",
"    On physical examination, granulation tissue is frequently visible in the inferior portion of the external auditory canal at the bone-cartilage junction (at the site of Santorini's fissures). However, this finding may be absent in atypical patients (eg, HIV-infected individuals and children).",
"   </p>",
"   <p>",
"    As the infection advances, osteomyelitis of the base of the skull and temporomandibular joint osteomyelitis can develop [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/3,6,41,42\">",
"     3,6,41,42",
"    </a>",
"    ]. Progression of the osteomyelitis can be associated with cranial nerve palsies. In one series of 23 adult diabetic patients with malignant external otitis, 10 patients had cranial nerve involvement; six had only facial nerve involvement, and four had a combination of nerves involved (VI, VII, IX, X, XI, XII) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/43\">",
"     43",
"    </a>",
"    ]. Children with malignant external otitis have a higher incidence of facial palsy due to their relatively undeveloped mastoid process and the more medial location of the fissures of Santorini, which places the facial nerve in closer proximity to the ear canal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/44\">",
"     44",
"    </a>",
"    ]. The glossopharyngeal, vagal, and spinal accessory nerves can be afflicted at the jugular foramen, and the hypoglossal nerve can be affected as it exits the hypoglossal canal. The trigeminal and abducens nerves are rarely affected at the petrous apex, and there is a single report of optic nerve involvement in a patient with malignant external otitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/45\">",
"     45",
"    </a>",
"    ]. The olfactory, oculomotor, and trochlear nerves appear to be unaffected by this disease.",
"   </p>",
"   <p>",
"    Other central nervous system complications are rare, but can be fatal when they occur. These include meningitis, brain abscess, and dural sinus thrombophlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/13/16600?source=see_link\">",
"     \"Epidemiology and clinical features of gram-negative bacillary meningitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23145?source=see_link\">",
"     \"Septic dural sinus thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is often overlooked, leading to delay in effective therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. In the absence of a single pathognomonic criterion, the diagnosis of malignant external otitis is based upon a constellation of clinical, laboratory, and radiographic findings. A retrospective review of 73 cases at a tertiary care center suggested that patients who present with most of the classic clinical and radiographic criteria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who fail to respond to the initial course of intensive therapy have worse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory parameters are generally normal in malignant external otitis, with the exception of an elevated erythrocyte sedimentation rate (ESR). Although nonspecific, a strikingly elevated ESR is the most characteristic laboratory abnormality and is a useful way of monitoring disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of nuclear imaging studies is controversial, whereas anatomic localizing procedures such as computed tomography (CT) and magnetic resonance imaging (MRI) can be useful for both diagnosis and follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone scanning with technetium Tc 99m, where the radionuclide tracer accumulates at sites of osteoblastic activity, is very sensitive in making the diagnosis. However, it is not a specific study since there are reports of positive bone scans in simple external otitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/47\">",
"     47",
"    </a>",
"    ], and bone scans are not suitable for following response to treatment since they do not normalize. Quantitative bone scanning may be able to distinguish simple from malignant external otitis and demonstrate disease resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gallium scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4978?source=see_link\">",
"     Gallium citrate Ga-67",
"    </a>",
"    scanning appears to be more specific than bone scanning since the radioisotope is incorporated into granulocytes and bacteria. Although several studies have reported that gallium scanning can be used to follow disease activity, others have noted that normal scans can be found in patients with recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/50-56\">",
"     50-56",
"    </a>",
"    ]. The combination of Ga 67 with single photon emission computerized tomography (SPECT) scanning is useful in the diagnosis and follow-up examination [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/15,54-56\">",
"     15,54-56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Computed tomography and magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anatomic imaging modalities allow for both anatomic localization of disease as well as the assessment of disease resolution. CT scanning is ideal for the assessment of bone erosion. In a prospective study, we determined that the presence of bone erosion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    soft tissue abnormalities in the subtemporal region was helpful in making the diagnosis of malignant external otitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/57\">",
"     57",
"    </a>",
"    ]. Although bone did not remineralize, resolution of the soft tissue component did correlate with disease activity. While some studies indicate that CT findings predict clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/58\">",
"     58",
"    </a>",
"    ], others have reported that the CT findings do not correlate with the clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To compare CT to MRI, we performed a long-term prospective study in seven patients with malignant external otitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/60\">",
"     60",
"    </a>",
"    ]. MRI was slightly better at demonstrating medial skull base disease due to its ability to delineate changes in the fat content of the marrow. Better results with MRI have also been noted by others [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/61\">",
"     61",
"    </a>",
"    ]. Retrocondylar fat extension on MRI may indicate the earliest change in malignant external otitis, with greater extension being associated with worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/62\">",
"     62",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma of the temporal bone can also present as a painful draining ear canal. Since radiographic studies cannot differentiate tumor from necrotizing infection, biopsy is the only definitive method to distinguish between these two entities. A positive culture for P. aeruginosa and elevation of the ESR are more commonly associated with infection. There are only two reports of simultaneous presentation of temporal bone cancer and malignant external otitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipseudomonal antimicrobials are the mainstay of therapy for malignant external otitis. Prior to the development of systemic agents, the mortality from this disease approximated 50 percent with frequent recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/4\">",
"     4",
"    </a>",
"    ]. Introduction of parenteral semisynthetic penicillins reduced the mortality to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/65\">",
"     65",
"    </a>",
"    ]. Oral fluoroquinolones have generally replaced combination therapy with aminoglycosides or third-generation cephalosporins in the treatment of malignant external otitis.",
"   </p>",
"   <p>",
"    With the introduction of fluoroquinolones, the cure rate has increased to 90 percent, with few adverse effects reported.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    (750 mg orally twice daily) remains the antibiotic of choice, although no comparative trials have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/66-72\">",
"     66-72",
"    </a>",
"    ]. We usually initiate treatment with intravenous ciprofloxacin (400 mg every eight hours) until we obtain a subjective clinical response",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a decrease in ESR. The remainder of the course of ciprofloxacin can be given orally.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     Levofloxacin",
"    </a>",
"    is also likely to be effective since it has pharmacodynamic activity against P. aeruginosa similar to ciprofloxacin, but clinical experience with levofloxacin has not been reported. Prolonged treatment for six to eight weeks is generally recommended, as indicated for osteomyelitis.",
"   </p>",
"   <p>",
"    With the introduction and widespread use of both oral and topical quinolones, less severe clinical presentation of malignant external otitis and the emergence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    resistance have been seen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/1,73\">",
"     1,73",
"    </a>",
"    ]. Patients with resistant P. aeruginosa require hospitalization for biopsy, debridement, and parenteral antibiotics (generally a prolonged course of an antipseudomonal beta lactam agent with or without an aminoglycoside).",
"   </p>",
"   <p>",
"    If Aspergillus species are the causative organisms, prolonged treatment (&gt;12 weeks) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is indicated. We recommend use of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    preparation to lower the incidence of nephrotoxicity, compared with non-liposomal amphotericin B. Success has also been reported with a short course of amphotericin B and long-term oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/74\">",
"     74",
"    </a>",
"    ]. Comparative data on the usefulness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    in this situation are not yet available, although voriconazole has been effective against Aspergillus in other infections and might avoid the toxicity of prolonged amphotericin (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is no role for topical antibiotics in malignant external otitis therapy. Instillation of antipseudomonal topical agents may only increase the difficulty in isolating the organism from the ear canal. Surgical excision also plays no role in the current treatment of this disease, although this modality was used prior to the availability of systemic antipseudomonal antibiotics. Debridement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy to rule out cancer are the only indicated surgical procedures.",
"   </p>",
"   <p>",
"    Hyperbaric oxygen has been used on occasion with mixed results and may be considered as an adjuvant treatment for refractory cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/41,75-78\">",
"     41,75-78",
"    </a>",
"    ]. However, a Cochrane review found no randomized controlled trials comparing hyperbaric oxygen therapy to treatment with antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery, and concluded that there was no clear evidence to demonstrate the efficacy of hyperbaric oxygen treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20216/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/2/15394?source=see_link\">",
"       \"Patient information: Outer ear infection (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26816?source=see_link\">",
"       \"Patient information: External otitis (including swimmer's ear) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5155068\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5155955\">",
"    <span class=\"h2\">",
"     Epidemiology, microbiology, and pathogenesis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant (necrotizing) external otitis (also termed malignant otitis externa) is an invasive infection of the external auditory canal and skull base, which typically occurs in elderly patients with diabetes mellitus. Malignant external otitis has been seen in HIV patients, implicating a compromised immune system as a predisposing factor in this disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignant external otitis is caused by Pseudomonas aeruginosa in more than 95 percent of cases. When more than one organism is recovered, isolates accompanying P. aeruginosa tend to be normal skin flora. Occasional reports of cases caused by other organisms have included Aspergillus species, Staphylococcus aureus, Proteus mirabilis, Klebsiella oxytoca, Burkholderia cepacia, and Candida parapsilosis. Infection with these other organisms characteristically occurs in immunocompromised hosts, such as those with AIDS or cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      P. aeruginosa is a ubiquitous gram-negative bacterium that is capable of growing in distilled water. Since it is not a normal component of ear canal flora even in diabetic patients, its recovery indicates the presence of a pathogen. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5155947\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with malignant external otitis classically present with exquisite otalgia and otorrhea, which are not responsive to topical measures used to treat simple external otitis. The pain is generally more severe than that found in simple external otitis, although the two may be difficult to distinguish in their early stages. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On physical examination, granulation tissue is frequently visible in the inferior portion of the external auditory canal at the bone-cartilage junction (at the site of Santorini's fissures). However, this finding may be absent in atypical patients (eg, HIV-infected individuals and children). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As the infection advances, osteomyelitis of the base of the skull and temporomandibular joint osteomyelitis can develop. Progression of the osteomyelitis can be associated with cranial nerve palsies. Other central nervous system complications are rare, but can be fatal when they occur. These include meningitis, brain abscess, and dural sinus thrombophlebitis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5155939\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of malignant external otitis is based upon a constellation of clinical, laboratory, and radiographic findings. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory parameters are generally normal in malignant external otitis, with the exception of an elevated erythrocyte sedimentation rate (ESR). Although nonspecific, a strikingly elevated ESR is the most characteristic laboratory abnormality and is a useful way of monitoring disease activity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anatomic localizing procedures, such as computed tomography, magnetic resonance imaging, and Gallium SPECT scans can be useful for both diagnosis and follow-up. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Squamous cell carcinoma of the temporal bone can also present as a painful draining ear canal. Since radiographic studies cannot differentiate tumor from necrotizing infection, biopsy is the only definitive method to distinguish between these two entities. A positive culture for P. aeruginosa and elevation of the ESR are more commonly associated with infection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5155963\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      (750 mg orally twice daily) remains the antibiotic of choice, although no comparative trials have been reported. We usually initiate treatment with intravenous ciprofloxacin (400 mg every eight hours) until we obtain a subjective clinical response",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a decrease in the ESR. The remainder of the course of ciprofloxacin can be given orally.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      is also likely to be effective since it has pharmacodynamic activity against P. aeruginosa similar to ciprofloxacin, but clinical experience with levofloxacin has not been reported. Prolonged treatment for six to eight weeks is generally recommended, as indicated for osteomyelitis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no role for topical antibiotics or surgical excision in malignant external otitis therapy. Debridement",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biopsy to obtain cultures or rule out cancer are the only indicated surgical procedures. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperbaric oxygen has been used on occasion with mixed results and may be considered as an adjuvant treatment for refractory cases. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/1\">",
"      Rubin Grandis J, Branstetter BF 4th, Yu VL. The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations. Lancet Infect Dis 2004; 4:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/2\">",
"      Bernstein JM, Holland NJ, Porter GC, Maw AR. Resistance of Pseudomonas to ciprofloxacin: implications for the treatment of malignant otitis externa. J Laryngol Otol 2007; 121:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/3\">",
"      Rubin J, Yu VL. Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med 1988; 85:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/4\">",
"      Chandler JR. Malignant external otitis. Laryngoscope 1968; 78:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/5\">",
"      Barrow HN, Levenson MJ. Necrotizing 'malignant' external otitis caused by Staphylococcus epidermidis. Arch Otolaryngol Head Neck Surg 1992; 118:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/6\">",
"      Farr RC, Gardner G, Acker JD, et al. Blastomycotic cranial osteomyelitis. Am J Otol 1992; 13:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/7\">",
"      Scott CF Jr, Tsurufuji M, Lu CY, et al. Comparison of antigen-specific T cell responses in autoimmune MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice. J Immunol 1984; 132:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/8\">",
"      Reiss P, Hadderingh R, Schot LJ, Danner SA. Invasive external otitis caused by Aspergillus fumigatus in two patients with AIDS. AIDS 1991; 5:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/9\">",
"      Rivas Lacarte MP, Pumarola Segura F. [Malignant otitis externa and HIV antibodies. A case report]. An Otorrinolaringol Ibero Am 1990; 17:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/10\">",
"      McElroy EA Jr, Marks GL. Fatal necrotizing otitis externa in a patient with AIDS. Rev Infect Dis 1991; 13:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/11\">",
"      Kielhofner M, Atmar RL, Hamill RJ, Musher DM. Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. Clin Infect Dis 1992; 14:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/12\">",
"      Weinroth SE, Schessel D, Tuazon CU. Malignant otitis externa in AIDS patients: case report and review of the literature. Ear Nose Throat J 1994; 73:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/13\">",
"      Ress BD, Luntz M, Telischi FF, et al. Necrotizing external otitis in patients with AIDS. Laryngoscope 1997; 107:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/14\">",
"      Mu&ntilde;oz A, Mart&iacute;nez-Chamorro E. Necrotizing external otitis caused by Aspergillus fumigatus: computed tomography and high resolution magnetic resonance imaging in an AIDS patient. J Laryngol Otol 1998; 112:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/15\">",
"      Jacobsen LM, Antonelli PJ. Errors in the diagnosis and management of necrotizing otitis externa. Otolaryngol Head Neck Surg 2010; 143:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/16\">",
"      Cunningham M, Yu VL, Turner J, Curtin H. Necrotizing otitis externa due to Aspergillus in an immunocompetent patient. Arch Otolaryngol Head Neck Surg 1988; 114:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/17\">",
"      Petrak, RM, Pottage, JC, Levin, S. Invasive external otitis caused by Aspergillus fumigatus in an immunocompromised patient. J Infect Dis 1985; 151:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/18\">",
"      Phillips P, Bryce G, Shepherd J, Mintz D. Invasive external otitis caused by Aspergillus. Rev Infect Dis 1990; 12:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/19\">",
"      Lyos AT, Malpica A, Estrada R, et al. Invasive aspergillosis of the temporal bone: an unusual manifestation of acquired immunodeficiency syndrome. Am J Otolaryngol 1993; 14:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/20\">",
"      Gordon G, Giddings NA. Invasive otitis externa due to Aspergillus species: case report and review. Clin Infect Dis 1994; 19:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/21\">",
"      Harley WB, Dummer JS, Anderson TL, Goodman S. Malignant external otitis due to Aspergillus flavus with fulminant dissemination to the lungs. Clin Infect Dis 1995; 20:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/22\">",
"      Bayardelle P, Jolivet-Granger M, Larochelle D. Staphylococcal malignant external otitis. Can Med Assoc J 1982; 126:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/23\">",
"      C&oacute;ser PL, Stamm AE, Lobo RC, Pinto JA. Malignant external otitis in infants. Laryngoscope 1980; 90:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/24\">",
"      Garcia Rodriguez JA, Montes Martinez I, G&oacute;mez Gonz&aacute;lez JL, et al. A case of malignant external otitis involving Klebsiella oxytoca. Eur J Clin Microbiol Infect Dis 1992; 11:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/25\">",
"      Dettelbach MA, Hirsch BE, Weissman JL. Pseudomonas cepacia of the temporal bone: malignant external otitis in a patient with cystic fibrosis. Otolaryngol Head Neck Surg 1994; 111:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/26\">",
"      Lancaster J, Alderson DJ, McCormick M. Non-pseudomonal malignant otitis externa and jugular foramen syndrome secondary to cyclosporin-induced hypertrichosis in a diabetic renal transplant patient. J Laryngol Otol 2000; 114:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/27\">",
"      Yao M, Messner AH. Fungal malignant otitis externa due to Scedosporium apiospermum. Ann Otol Rhinol Laryngol 2001; 110:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/28\">",
"      Chai FC, Auret K, Christiansen K, et al. Malignant otitis externa caused by Malassezia sympodialis. Head Neck 2000; 22:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/29\">",
"      Favero MS, Carson LA, Bond WW, Petersen NJ. Pseudomonas aeruginosa: growth in distilled water from hospitals. Science 1971; 173:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/30\">",
"      Yoshpe-Purer Y, Golderman S. Occurrence of Staphylococcus aureus and Pseudomonas aeruginosa in Israeli coastal water. Appl Environ Microbiol 1987; 53:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/31\">",
"      Wright DN, Alexander JM. Effect of water on the bacterial flora of swimmers' ears. Arch Otolaryngol 1974; 99:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/32\">",
"      Salit IE, Miller B, Wigmore M, Smith JA. Bacterial flora of the external canal in diabetics and non-diabetics. Laryngoscope 1982; 92:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/33\">",
"      Manni JJ, Kuylen K. Clinical and bacteriological studies in otitis externa in Dar es Salaam, Tanzania. Clin Otolaryngol Allied Sci 1984; 9:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/34\">",
"      Seyfried PL, Cook RJ. Otitis externa infections related to Pseudomonas aeruginosa levels in five Ontario lakes. Can J Public Health 1984; 75:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/35\">",
"      Rubin J, Yu VL, Kamerer DB, Wagener M. Aural irrigation with water: a potential pathogenic mechanism for inducing malignant external otitis? Ann Otol Rhinol Laryngol 1990; 99:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/36\">",
"      Dinapoli RP, Thomas JE. Neurologic aspects of malignant external otitis: report of three cases. Mayo Clin Proc 1971; 46:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/37\">",
"      Schwarz GA, Blumenkrantz MJ, Sundm&auml;ker WL. Neurologic complications of malignant external otitis. Neurology 1971; 21:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/38\">",
"      John AC, Hopkin NB. An unusual case of necrotizing otitis externa. J Laryngol Otol 1978; 92:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/39\">",
"      Ford GR, Courteney-Harris RG. Another hazard of ear syringing: malignant external otitis. J Laryngol Otol 1990; 104:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/40\">",
"      Zikk D, Rapoport Y, Himelfarb MZ. Invasive external otitis after removal of impacted cerumen by irrigation. N Engl J Med 1991; 325:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/41\">",
"      Davis JC, Gates GA, Lerner C, et al. Adjuvant hyperbaric oxygen in malignant external otitis. Arch Otolaryngol Head Neck Surg 1992; 118:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/42\">",
"      Sreepada GS, Kwartler JA. Skull base osteomyelitis secondary to malignant otitis externa. Curr Opin Otolaryngol Head Neck Surg 2003; 11:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/43\">",
"      Mani N, Sudhoff H, Rajagopal S, et al. Cranial nerve involvement in malignant external otitis: implications for clinical outcome. Laryngoscope 2007; 117:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/44\">",
"      Horn KL, Gherini S. Malignant external otitis of childhood. Am J Otol 1981; 2:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/45\">",
"      Holder CD, Gurucharri M, Bartels LJ, Colman MF. Malignant external otitis with optic neuritis. Laryngoscope 1986; 96:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/46\">",
"      Joshua BZ, Sulkes J, Raveh E, et al. Predicting outcome of malignant external otitis. Otol Neurotol 2008; 29:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/47\">",
"      Levin WJ, Shary JH 3rd, Nichols LT, Lucente FE. Bone scanning in severe external otitis. Laryngoscope 1986; 96:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/48\">",
"      Uri N, Gips S, Front A, et al. Quantitative bone and 67Ga scintigraphy in the differentiation of necrotizing external otitis from severe external otitis. Arch Otolaryngol Head Neck Surg 1991; 117:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/49\">",
"      Stokkel MP, Takes RP, van Eck-Smit BL, Baatenburg de Jong RJ. The value of quantitative gallium-67 single-photon emission tomography in the clinical management of malignant external otitis. Eur J Nucl Med 1997; 24:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/50\">",
"      Ostfeld E, Aviel A, Pelet D. Malignant external otitis: The diagnostic value of bone scintigraphy. Laryngoscope 1981; 91:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/51\">",
"      Garty I, Rosen G, Holdstein Y. The radionuclide diagnosis, evaluation and follow-up of malignant external otitis (MEO). The value of immediate blood pool scanning. J Laryngol Otol 1985; 99:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/52\">",
"      Gherini SG, Brackmann DE, Bradley WG. Magnetic resonance imaging and computerized tomography in malignant external otitis. Laryngoscope 1986; 96:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/53\">",
"      Hardoff R, Gips S, Uri N, et al. Semiquantitative skull planar and SPECT bone scintigraphy in diabetic patients: differentiation of necrotizing (malignant) external otitis from severe external otitis. J Nucl Med 1994; 35:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/54\">",
"      Stokkel MP, Boot CN, van Eck-Smit BL. SPECT gallium scintigraphy in malignant external otitis: initial staging and follow-up. Case reports. Laryngoscope 1996; 106:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/55\">",
"      Paramsothy M, Khanijow V, Ong TO. Use of gallium-67 in the assessment of response to antibiotic therapy in malignant otitis externa--a case report. Singapore Med J 1997; 38:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/56\">",
"      Amorosa L, Modugno GC, Pirodda A. Malignant external otitis: review and personal experience. Acta Otolaryngol Suppl 1996; 521:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/57\">",
"      Rubin J, Curtin HD, Yu VL, Kamerer DB. Malignant external otitis: utility of CT in diagnosis and follow-up. Radiology 1990; 174:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/58\">",
"      Peleg U, Perez R, Raveh D, et al. Stratification for malignant external otitis. Otolaryngol Head Neck Surg 2007; 137:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/59\">",
"      Sudhoff H, Rajagopal S, Mani N, et al. Usefulness of CT scans in malignant external otitis: effective tool for the diagnosis, but of limited value in predicting outcome. Eur Arch Otorhinolaryngol 2008; 265:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/60\">",
"      Grandis JR, Curtin HD, Yu VL. Necrotizing (malignant) external otitis: prospective comparison of CT and MR imaging in diagnosis and follow-up. Radiology 1995; 196:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/61\">",
"      Ismail H, Hellier WP, Batty V. Use of magnetic resonance imaging as the primary imaging modality in the diagnosis and follow-up of malignant external otitis. J Laryngol Otol 2004; 118:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/62\">",
"      Lee JE, Song JJ, Oh SH, et al. Prognostic value of extension patterns on follow-up magnetic resonance imaging in patients with necrotizing otitis externa. Arch Otolaryngol Head Neck Surg 2011; 137:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/63\">",
"      Mattucci KF, Setzen M, Galantich P. Necrotizing otitis externa occurring concurrently with epidermoid carcinoma. Laryngoscope 1986; 96:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/64\">",
"      Grandis JR, Hirsch BE, Yu VL. Simultaneous presentation of malignant external otitis and temporal bone cancer. Arch Otolaryngol Head Neck Surg 1993; 119:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/65\">",
"      Soliman AE. A rare case of malignant otitis externa in a non-diabetic patient. J Laryngol Otol 1978; 92:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/66\">",
"      Joachims HZ, Danino J, Raz R. Malignant external otitis: treatment with fluoroquinolones. Am J Otolaryngol 1988; 9:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/67\">",
"      Leggett JM, Prendergast K. Malignant external otitis: the use of oral ciprofloxacin. J Laryngol Otol 1988; 102:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/68\">",
"      Morrison GA, Bailey CM. Relapsing malignant otitis externa successfully treated with ciprofloxacin. J Laryngol Otol 1988; 102:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/69\">",
"      Sad&eacute; J, Lang R, Goshen S, Kitzes-Cohen R. Ciprofloxacin treatment of malignant external otitis. Am J Med 1989; 87:138S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/70\">",
"      Hickey SA, Ford GR, O'Connor AF, et al. Treating malignant otitis with oral ciprofloxacin. BMJ 1989; 299:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/71\">",
"      Rubin J, Stoehr G, Yu VL, et al. Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis. Arch Otolaryngol Head Neck Surg 1989; 115:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/72\">",
"      Levenson MJ, Parisier SC, Dolitsky J, Bindra G. Ciprofloxacin: drug of choice in the treatment of malignant external otitis (MEO). Laryngoscope 1991; 101:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/73\">",
"      Berenholz L, Katzenell U, Harell M. Evolving resistant pseudomonas to ciprofloxacin in malignant otitis externa. Laryngoscope 2002; 112:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/74\">",
"      Finer G, Greenberg D, Leibovitz E, et al. Conservative treatment of malignant (invasive) external otitis caused by Aspergillus flavus with oral itraconazole solution in a neutropenic patient. Scand J Infect Dis 2002; 34:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/75\">",
"      Shupak A, Greenberg E, Hardoff R, et al. Hyperbaric oxygenation for necrotizing (malignant) otitis externa. Arch Otolaryngol Head Neck Surg 1989; 115:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/76\">",
"      Mader JT, Love JT. Malignant external otitis. Cure with adjunctive hyperbaric oxygen therapy. Arch Otolaryngol 1982; 108:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/77\">",
"      Lucente FE, Parisier SC, Som PM, Arnold LM. Malignant external otitis: a dangerous misnomer? Otolaryngol Head Neck Surg 1982; 90:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/78\">",
"      Lucente FE, Parisier SC, Som PM. Complications of the treatment of malignant external otitis. Laryngoscope 1983; 93:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20216/abstract/79\">",
"      Phillips JS, Jones SE. Hyperbaric oxygen as an adjuvant treatment for malignant otitis externa. Cochrane Database Syst Rev 2005; :CD004617.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3413 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-813CF6A707-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20216=[""].join("\n");
var outline_f19_47_20216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5155068\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bone scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gallium scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Computed tomography and magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5155068\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5155955\">",
"      Epidemiology, microbiology, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5155947\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5155939\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5155963\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/13/16600?source=related_link\">",
"      Epidemiology and clinical features of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27145?source=related_link\">",
"      Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=related_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32503?source=related_link\">",
"      Other Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26816?source=related_link\">",
"      Patient information: External otitis (including swimmer's ear) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/2/15394?source=related_link\">",
"      Patient information: Outer ear infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14775?source=related_link\">",
"      Pseudomonas aeruginosa bacteremia and endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=related_link\">",
"      Pseudomonas aeruginosa pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=related_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23145?source=related_link\">",
"      Septic dural sinus thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_47_20217="Clinical presentation, diagnosis, and staging of bladder cancer";
var content_f19_47_20217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation, diagnosis, and staging of bladder cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20217/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20217/contributors\">",
"     Yair Lotan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20217/contributors\">",
"     Toni K Choueiri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20217/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20217/contributors\">",
"     Seth P Lerner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20217/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20217/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/47/20217/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer is the most common malignancy involving the urinary system. Urothelial (transitional cell) carcinoma is the predominant histologic type in the United States and Europe, where it accounts for 90 percent of all bladder cancers. In other areas of the world, non-urothelial carcinomas are more frequent. Much less commonly, urothelial cancers can arise in the renal pelvis, ureter, or urethra. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spectrum of bladder cancer includes non-muscle-invasive (superficial), muscle-invasive, and metastatic disease, each with its own clinical behavior, prognosis, and treatment.",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and staging of bladder cancer will be presented here.",
"   </p>",
"   <p>",
"    The management of patients with bladder cancer, including specific recommendations based upon the stage of disease, is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overview of bladder cancer treatment (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2759?source=see_link\">",
"       \"Overview of the management of urothelial (transitional cell) bladder cancer\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Non-muscle-invasive bladder cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link\">",
"       \"Treatment of non-muscle-invasive bladder cancer\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Muscle invasive bladder cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=see_link\">",
"       \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=see_link\">",
"       \"Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Metastatic bladder cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=see_link\">",
"       \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bladder cancer classically present with painless hematuria, although irritative voiding symptoms (frequency, urgency, dysuria) can be the initial manifestation. The diagnosis is often delayed due to the similarity of these symptoms to those of benign disorders (urinary tract infection, interstitial cystitis, prostatitis, passage of renal calculi), and delays can lead to a worsened prognosis due to more advanced stage at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, symptoms are often intermittent. In some patients, metastases will cause the initial symptoms. Incidental bladder cancer is rare at autopsy, suggesting that most cancers eventually become symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting symptom is hematuria, which is typically intermittent, gross, painless, and present throughout micturition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The likelihood of bladder cancer depends on whether the hematuria is gross (visible) or microscopic, with some studies diagnosing bladder cancer in 10 to 20 percent of patients with gross hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In those evaluated for microscopic hematuria, the reported incidence of bladder cancer ranges between 2 and 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/3,5-7\">",
"     3,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, 9 to 18 percent of apparently normal individuals have some hematuria, and hematuria is due to benign causes in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/5,6,8\">",
"     5,6,8",
"    </a>",
"    ]. The number of red blood cells in the urine is not predictive of the probability of cancer.",
"   </p>",
"   <p>",
"    The importance of evaluating hematuria was illustrated by a study of 1930 patients, in which 61 percent had no abnormality diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/3\">",
"     3",
"    </a>",
"    ]. Abnormalities that were found included bladder cancer (12 percent), urinary tract infections (13 percent), medical renal disease (10 percent), stone disease (4 percent), kidney cancer (0.6 percent) and prostate cancer (0.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/3\">",
"     3",
"    </a>",
"    ]. Bladder cancer was much more frequent in older patients, but seven patients with bladder cancer were younger than 40 years, including one with microscopic hematuria.",
"   </p>",
"   <p>",
"    The point at which gross hematuria is noted during urination can be helpful in localizing its source:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematuria occurring primarily at the beginning of urination is usually from a urethral source.",
"     </li>",
"     <li>",
"      Blood that is only noticed as a discharge between voidings, or as a stain on undergarments, while the voided urine itself appears clear, indicates an origin at the urethral meatus or the anterior urethra.",
"     </li>",
"     <li>",
"      Terminal hematuria, with blood appearing towards the end of voiding, generally originates from the bladder neck or prostatic urethra.",
"     </li>",
"     <li>",
"      Hematuria occurring throughout voiding can originate from anywhere in the urinary tract including the bladder, ureters, or kidneys.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain associated with bladder cancer is usually the result of locally advanced or metastatic tumor. Its distribution is related to the size and location of the primary tumor or its metastases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flank pain may result when a tumor obstructs the ureter at any level (bladder, ureter or renal pelvis). Although obstruction usually is associated with muscle-invasive disease, large non-invasive tumors at the ureteral orifice may also cause symptoms. The pain is similar to that experienced with the passage of urinary stones, and may or may not be associated with hematuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link\">",
"       \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Suprapubic pain is usually a sign of a locally advanced tumor that is either directly invading the perivesical soft tissues and nerves, or obstructing the bladder outlet and causing urinary retention.",
"     </li>",
"     <li>",
"      Hypogastric and perineal pain can be signs of disease invading the obturator fossa, presacral nerves, or the urogenital diaphragm.",
"     </li>",
"     <li>",
"      Abdominal or right upper quadrant pain may signal the presence of abdominal lymph node or liver metastases.",
"     </li>",
"     <li>",
"      Bone pain may indicate the presence of bone metastases.",
"     </li>",
"     <li>",
"      Significant and persistent headache or disordered cognitive function may suggest the presence of intracranial metastases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Voiding symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Voiding symptoms are most common in patients with carcinoma in situ (CIS) of the bladder, and may result from a functional decrease in the bladder capacity, detrusor overactivity, invasion of the trigone, or obstruction of the bladder neck or urethra.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irritative voiding symptoms (eg, daytime",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nocturnal frequency, urgency, dysuria, or urge incontinence) occur in approximately one-third of patients. The complex of dysuria, frequency, and urgency in particular is highly suggestive of bladder CIS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link\">",
"       \"Treatment of non-muscle-invasive bladder cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obstructive voiding symptoms are less common and may be due to tumor location at the bladder neck or prostatic urethra. Symptoms include straining, an intermittent stream, nocturia, decreased force of stream, and a feeling of incomplete voiding. On occasion, gross hematuria may result in \"clot retention\".",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Constitutional symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms such as fatigue, weight loss, anorexia, and failure to thrive are usually signs of advanced or metastatic disease and denote a poor prognosis. In rare cases, patients may have constitutional symptoms due to renal failure, caused by bilateral ureteral obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete physical examination should be performed in patients with bladder cancer, including a digital rectal examination in men and a bimanual examination of the vagina and rectum in women.",
"   </p>",
"   <p>",
"    Although the physical examination is unremarkable in most patients, abnormal findings that can be seen include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A solid pelvic mass may be felt in advanced cases.",
"     </li>",
"     <li>",
"      Induration of the prostate gland can sometimes be felt on digital rectal examination if the bladder cancer involves the bladder neck and invades the prostate. An attempt to palpate the base and lateral walls of the bladder should be made looking for induration or fixation.",
"     </li>",
"     <li>",
"      Inguinal adenopathy can be present, although the inguinal region is not common sites of node metastases.",
"     </li>",
"     <li>",
"      Nodularity in the periumbilical region can be seen in advanced lesions involving the dome of the bladder. This is often seen with urachal cancers, which typically are adenocarcinomas rather than urothelial tumors.",
"     </li>",
"     <li>",
"      Abdominal examination may reveal the presence of substantially enlarged para-aortic lymph nodes or hepatic metastases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of otherwise unexplained hematuria denotes a urothelial cancer in individuals over the age of 40 until proven otherwise. The goal of the diagnostic evaluation is to determine the diagnosis, site, and extent of cancer, and the presence or absence of muscle-invasive disease.",
"   </p>",
"   <p>",
"    A full urologic evaluation of the",
"    <strong>",
"     entire",
"    </strong>",
"    urinary tract is indicated in such patients unless there is clear evidence of glomerular bleeding (eg, red cell casts, proteinuria, dysmorphic red cells [particularly acanthocytes], and, in patients with gross hematuria, a smoky brown color). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This evaluation should consist of cystourethroscopy, urinary cytology, and an evaluation of the upper tracts, since urothelial malignancy can be multifocal, with one or more lesions anywhere from the renal pelvis to the proximal urethra.",
"   </p>",
"   <p>",
"    Radiographic imaging of the upper tract can consist of either a helical computed tomography (CT) scan of the",
"    <span class=\"nowrap\">",
"     abdomen/pelvis",
"    </span>",
"    with urography or intravenous pyelography (IVP) plus nephrograms or renal ultrasound (US) to evaluate both the collecting systems and the renal cortex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinalysis should include a microscopic and gross examination, as well as a dipstick chemical test. Nonrefrigerated urine should be examined within 30 minutes of collection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The average individual excretes about 30,000 RBCs per hour, which equates to about 1 RBC per high power field (HPF) on microscopic examination. Hematuria is usually not considered significant unless there are more than 3 RBCs per HPF. RBC morphology may also suggest the etiology of the hematuria; cells of glomerular origin are often dysmorphic or formed in casts, indicating intrinsic renal disease, while normally shaped RBCs are more likely from an extrinsic source such as calculi, tumor, obstruction, or infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urine color can be affected by its concentration, ingestion of certain foods or drugs, or the presence of bacteria, and can be confused with hematuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary pigments that can mimic hematuria include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Betalaine contained in beets (beeturia)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/7/41075?source=see_link\">",
"       Phenazopyridine",
"      </a>",
"      , a urinary analgesic",
"     </li>",
"     <li>",
"      Vegetable dyes",
"     </li>",
"     <li>",
"      Urates",
"     </li>",
"     <li>",
"      Free myoglobin or hemoglobin",
"     </li>",
"     <li>",
"      Serratia marcescens",
"     </li>",
"     <li>",
"      Phenolphthalein, which used to be a common component of many over-the-counter laxatives",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On occasion, dipstick analysis will be positive for blood, but microscopic examination fails to show RBCs. This can occur when myoglobin is present in the urine since it is chemically similar to hemoglobin. This can also occur when the red blood cells are lysed and in the presence of hemoglobin occurring in the course of hemolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4221132#H4221132\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Urine dipstick'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The specific gravity of a specimen is important to note because of its influence on the stability of white blood cells or RBCs. For example, when the urinary flow rate is high and the urine is very dilute, RBCs are lysed and therefore will not be present on microscopic examination even in the presence of pathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cystoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoscopy is the gold standard for the initial diagnosis and staging of bladder cancer. This procedure is done in the office with a flexible cystoscope and only has minimal risks such as bleeding and infection. Risk of infection can be reduced by using sterile technique and peri-procedural antibiotics. In the United States, this is typically done with white light; fluorescence cystoscopy is often used in some other regions. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Fluorescence cystoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Despite its utility, cystoscopy can miss tumors during the initial transurethral resection of bladder tumors (TURBT). This problem is illustrated by a study that showed that lesions discovered on repeat cystoscopy were usually tumors missed during the initial TURBT rather than true recurrences. The number of recurrences was 3 to 21 percent for single tumors and 7 to 46 percent for multiple tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/9\">",
"     9",
"    </a>",
"    ]. On the other hand, the problem is even greater for patients with CIS, in whom studies show that only 38 percent of lesions were detected with normal white-light cystoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a suspicious lesion is seen, repeat cystoscopy is performed. The procedure begins with a bimanual examination under anesthesia (EUA) to determine whether or not a palpable mass is present and, if present, whether or not it is mobile. An EUA during cystoscopy is effective at identifying locally advanced disease, which may present as gross extravesical extension, invasion of adjacent organs, or pelvic sidewall involvement. If a mass is felt, the bimanual exam is repeated after the resection to see if it is still present and to differentiate between clinical stage T2 and T3b disease (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"UTD.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H25\">",
"     'TNM staging system'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The cystoscope is then inserted into the bladder, and urine is obtained for cytology. The bladder is inspected visually, and a detailed description of the size, number, appearance, location, and growth pattern (papillary or solid) of all lesions is recorded. This information serves as a reference for subsequent cystoscopic examinations. The status of the uninvolved mucosa is also noted.",
"   </p>",
"   <p>",
"    In general, low-grade, non-invasive tumors are papillary with a narrow stalk. High-grade, invasive tumors frequently can appear sessile, solid, or nodular. Carcinoma in situ (CIS) is a high-grade, non-invasive tumor, which can appear as a flat velvety lesion and can arise in patches. CIS sometimes involve large parts of the urothelial lining. The size, stalk and configuration of the cancer can be predictive of muscle invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visible tumors are either biopsied or resected transurethrally to determine the histology and depth of invasion into the submucosa and muscle layers of the bladder. For patients undergoing repeat diagnostic cystoscopy after a prior transurethral resection of bladder tumors (TURBT), repeat biopsy should be obtained from areas that were previously resected. Even if these areas appear uninvolved, muscle-invasive disease will be detected in about one-third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsy specimens from grossly normal transitional cell epithelium and prostatic urethra should also be obtained to assess for a field effect. The presence of CIS, especially if it is diffuse, is associated with a high frequency of tumor recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with positive urine cytology and no visually apparent tumor within the bladder, biopsy of apparently normal urothelium and selective catheterization of the ureters with urine specimens for cytology from each ureter is required.",
"   </p>",
"   <p>",
"    Clinical staging is based on information derived from bimanual exam and imaging studies, as well as pathology results from the cystoscopic biopsy or TURBT. However, the initial pathology obtained from cystoscopy specimens does not always accurately stage the tumor.",
"   </p>",
"   <p>",
"    The limitations of clinical staging are illustrated by a study of 778 consecutive patients with bladder urothelial carcinoma who were treated with radical cystectomy and pelvic lymphadenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/14\">",
"     14",
"    </a>",
"    ]. Pathologic up-staging occurred in 42 percent of patients. This included patients thought to have non-muscle-invasive disease who had muscle-invasion in the pathologic specimen, and those thought to have organ-confined clinical stage in whom non-organ confined tumor was identified (&ge;pT3N0 or pTanyNpositive, (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"UTD.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    )). Pathologic down-staging occurred in 22 percent of cases.",
"   </p>",
"   <p>",
"    The detection of lymph node metastases with imaging is poor. About 20 to 30 percent of patients who undergo cystectomy with node negative disease by CT criteria have positive nodes at lymphadenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fluorescence cystoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluorescence cystoscopy uses an intravesical photoactive substance (such as 5-aminolevulinic acid [5-ALA]), which accumulates preferentially in neoplastic rather than normal tissue. The photoactive substance enhances the visual difference between normal and neoplastic tissue after illumination with light of the appropriate wavelength [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have confirmed that fluorescence cystoscopy detects more tumors (particularly CIS) than white-light cystoscopy, and this improved tumor identification results in a better patient management. The safety profile of fluorescence cystoscopy is excellent. The improved early detection and treatment of tumors need to be balanced by a slightly higher false-positive rate (mainly due to inflammation and scarring), the requirement for a special lens system, the need to instill the photosensitizer one hour prior to cystoscopy, and the need for rigid rather than flexible cystoscopy, as well as the higher cost. The clinical results with fluorescence endoscopy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Fluorescence endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Urine cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytology is commonly used as an adjunct to cystoscopy to detect CIS and upper tract malignancies. The underlying concept is that cells in the urinary tract that are proliferating rapidly will be exfoliated. However, urine cytology has a relatively poor sensitivity, particularly for low-grade tumors. This was illustrated by a meta-analysis that included 18 studies with 1255 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/18\">",
"     18",
"    </a>",
"    ]. The overall sensitivity was 34 percent, with sensitivities for grade 1, 2, and 3 tumors of 12, 26 and 64 percent, respectively.",
"   </p>",
"   <p>",
"    Lower grade tumors have fewer morphologic alterations that may lead to the loss of intercellular attachments and adhesiveness. Thus, they may not exfoliate as easily as higher grade tumors. When they are exfoliated, low grade tumors are shed in large papillary fragments with uniform size, minimal alterations in nuclear to cytoplasmic ratio, and small or absent nucleoli. Higher grade tumor cells tend to be more isolated in loose clusters and elongated with marked pleomorphism, increased nuclear to cytoplasmic ratios, and variable nucleoli size.",
"   </p>",
"   <p>",
"    False positive results are rare with urine cytology (specificity &gt;98 percent in most studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus any positive cytology should be assumed to represent malignancy. If no disease is evident in the bladder, the upper urinary tracts and prostatic urethra should be thoroughly evaluated. If no lesion is discernible, selective ureteral and renal pelvis washings may be performed; however, the diagnostic accuracy of these procedures is debated because of possible contamination from the bladder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=see_link\">",
"     \"Malignancies of the renal pelvis and ureter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urine cytology specimens must be properly collected and stored in order to maintain a high level of diagnostic accuracy. Catheterized specimens can denude normal surface epithelial cells; coalescence in papillary groups may be misinterpreted as low grade TCC. Voided specimens with prolonged exposure to concentrated urine, or specimens from women that are contaminated with vaginal, cervical, or endometrial cells can also be misinterpreted. A recent study showed a lower diagnostic yield with voided urine specimens when compared with bladder washings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/19\">",
"     19",
"    </a>",
"    ]. Chronic urinary tract infections, inflammatory conditions, stone disease, recent instrumentation or intravesical therapy, and bowel substitutions for the bladder (eg, ileal conduits or orthotopic neobladders) can create degenerative cellular changes and atypia, which can be misinterpreted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32298?source=see_link\">",
"     \"Urinary diversion and reconstruction following cystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Urine-based markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple urine-based tumor markers have been developed because of the low sensitivity of cytology and the need for a non-invasive diagnostic tool to supplement cystoscopy. These urine biomarkers are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40041?source=see_link\">",
"     \"Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These tests either identify proteins in urine with increased expression in cancer cells, detect cellular antigens by immunohistochemistry or cytochemistry, or use fluorescent in situ hybridization (FISH) to identify genetic alterations associated with bladder cancer. Several of these markers are approved either for diagnosis or surveillance in patients with a history of bladder cancer; other tests are in development.",
"   </p>",
"   <p>",
"    None of these markers have sufficient sensitivity to replace cystoscopy in the assessment of an individual suspected to have bladder cancer, and their clinical use has not been recommended by consensus panels. There is a potential benefit for surveillance in patients with a history or urothelial cancer by reducing the interval for cystoscopy. A positive biomarker test in conjunction with a negative cystoscopy can be problematic, since these tests occasionally will detect an urothelial tumor of the upper urinary tract or a lesion missed at cystoscopy. As an example, a prospective study of 200 patients with non-muscle-invasive bladder cancer compared the accuracy and cost of cystoscopy alone and cystoscopy combined with cytology, FISH and NMP-22, and found that despite their added costs, additional tests did not improve results compared to cystoscopy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional clinical trials are necessary to determine the incremental benefit of markers and the cost-effectiveness of their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Urinary tract imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies may be used to define the location and extent of tumor, as well as to detect sites of multifocal disease. CT scan is replacing the intravenous pyelogram (IVP) as the procedure of choice, but IVP remains an appropriate alternative where CT is not readily available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scans should include both the abdomen and pelvis, need to be done with and without contrast, and should include delayed images to identify defects in the collecting system. CT may demonstrate extravesical extension, nodal involvement in the pelvis or retroperitoneum, visceral, pulmonary or osseous metastasis, and tumor involvement or obstruction of the upper urinary tract.",
"   </p>",
"   <p>",
"    Although CT provides better visualization of tumors than US, it may miss tumors &lt;1 cm in size, particularly those in the bladder trigone or dome, and cannot differentiate depth of bladder wall invasion (ie, mucosal versus lamina propria or muscularis propria).",
"   </p>",
"   <p>",
"    Although a thickened bladder wall on CT suggests the presence of muscle-invasive disease, tissue is required for diagnosis. In contrast, CT is about 80 percent accurate in differentiating locally advanced tumors involving extravesical adipose tissue or surrounding structures from less invasive tumors (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52521 \" href=\"UTD.htm?14/42/15011\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/21\">",
"     21",
"    </a>",
"    ]. An important caveat is that in most instances, CT is performed after a transurethral resection, which complicates its interpretation. It may be difficult to distinguish inflammatory or iatrogenic edematous changes from true extravesical tumor extension.",
"   </p>",
"   <p>",
"    The sensitivity of CT for identification of nodal involvement is relatively low (false negative rate 68 percent, false positive rate 16 percent) and requires a needle or excisional biopsy for confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Intravenous pyelogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;An IVP can visualize both the bladder and upper urinary tracts. IVP is an appropriate choice for patients with microscopic or gross hematuria or suspected urothelial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/3,23\">",
"     3,23",
"    </a>",
"    ]. IVP is more sensitive for detection of small lesions of the ureter or renal pelvis, while CT scan or renal ultrasound (US) are better tests for the evaluation of renal parenchymal disease. Ideally, the IVP should be obtained prior to the transurethral resection of the tumor to avoid misinterpretation of postoperative changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IVP may not be appropriate in patients with renal insufficiency, diabetes mellitus, or other conditions, due to the risk of acute renal injury. IVP may also not be appropriate in patients with a history of allergies to radiocontrast agents, although prophylactic corticosteroids and antihistamines may be useful. In patients in whom the ureters and renal pelvis are poorly visualized by IVP, retrograde pyelograms may be performed during cystoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=see_link&amp;anchor=H13#H13\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\", section on 'Primary prevention of IHRs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cystogram phase of the IVP detects 60 to 85 percent of large bladder tumors, but smaller tumors are missed more frequently. Both the cystogram phase and the post void film should be examined for filling defects (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68718 \" href=\"UTD.htm?6/52/6976\">",
"     image 2",
"    </a>",
"    ), which are usually irregular, frond-like, or nodular, and persistent from film to film. Filling defects may be the result of parietal tumor implantation, the uneven jagged contours of papillary fronds, or obstruction of a ureter with proximal dilation. The classic urographic findings of an upper tract TCC is a meniscus-shaped ureteral filling defect known as the \"goblet\" or \"Bergmann\" sign, and the \"stipple sign\" produced by contrast being trapped in the fronds of a papillary tumor (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56915 \" href=\"UTD.htm?2/8/2191\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    About 50 percent of patients with a filling defect in the renal pelvis or ureter will have associated hydronephrosis, hydroureter, or nonvisualization of the kidney secondary to obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/24\">",
"     24",
"    </a>",
"    ]. Invasive bladder tumors may cause distal ureteral obstruction and secondary hydronephrosis. Although the lack of this finding does not rule out invasive disease, its presence signals an invasive cancer in over 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/21\">",
"     21",
"    </a>",
"    ]. Nonvisualization of the kidney is usually seen in advanced disease and is frequently associated with invasion of tumor into the renal parenchyma. Stenosis is also a specific sign of infiltrating disease and is more commonly seen in the ureter (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75824 \" href=\"UTD.htm?1/22/1377\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is as reliable as CT for staging of invasive or locally advanced disease, and may be better at evaluating tumors at the base and dome of the bladder. Gadolinium-enhanced MRI may be superior to CT to detect superficial and multiple tumors, extravesical tumor extension, and surrounding organ invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although MRI is useful for patients with contrast dye allergy, it is difficult to tolerate by claustrophobic patients and cannot be used in patients with pacemakers or other metallic foreign bodies. Open MRI imaging may be better tolerated, but image resolution is poorer due to the smaller magnet used with this modification in imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound (US) is not very useful for the diagnosis or staging of bladder cancer. US can confirm the presence of a soft tissue mass, but usually cannot determine depth of invasion, extravesical extension, or nodal status. US may be useful in evaluating the upper tracts for renal parenchymal disease, hydronephrosis, and to differentiate a non-radiopaque stone from a soft tissue mass by differences in echogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Imaging for metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis and clinical stage of bladder cancer are established, other imaging studies may be useful to evaluate for metastatic disease.",
"   </p>",
"   <p>",
"    The decision whether or not to perform additional diagnostic studies is based upon the results of the physical and bimanual examination, cystoscopy and the",
"    <span class=\"nowrap\">",
"     histologic/cytologic",
"    </span>",
"    evaluation. Because bladder tumors often occur in the elderly, a general medical evaluation is also essential to document significant comorbid conditions which might interfere with appropriate treatment regimens (ie, ability to tolerate general anesthesia, prolonged surgery, chemotherapy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Lung lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs are used for the initial evaluation and for periodic monitoring in patients at risk for pulmonary metastasis, although they are insensitive for lesions &lt;1 cm. Metastatic lesions are typically non-calcified soft tissue densities. Although CT scans of the chest have too many false positive results to use for routine screening, CT may be valuable if there are abdominal metastases or positive lymph node, or if the chest film is suspicious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide bone scans to detect bone metastases are recommended only in patients with invasive or locally advanced tumors and either skeletal symptoms or unexplained elevations in serum alkaline phosphatase. Increased uptake is a nonspecific finding, which may be due to degenerative change, trauma, and previous fracture sites, as well as metastatic disease. Plain radiographs, CT, or MRI of suspicious areas may be necessary to confirm a metastasis. Bone biopsy can be performed to document metastatic disease if necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     PET",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET has limited value and does not yet have an established role in patients with localized bladder cancer due to urinary excretion of 18F-fluorodeoxyglucose (FDG) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preoperatively",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is a promising tool to detect metastatic disease, although its use remains experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a study of 55 patients with bladder cancer, integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    improved the preoperative NM staging compared with CT alone in 15 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PET may have a larger role in detecting disseminated disease. In another study, 46 patients were evaluated with PET scans [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/33\">",
"     33",
"    </a>",
"    ]. Sensitivity for metastases to adrenal, bone, kidney, lymph node, and soft tissue were all 80 percent or greater.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     HISTOLOGIC GRADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization and the International Society of Urologic Pathologists have established a consensus classification system for urothelial (transitional cell) neoplasms, in which urothelial cancer is classified as low-grade and high-grade. With rare exceptions, invasive urothelial cancer is high-grade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27481?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathology of bladder neoplasms\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TNM STAGING SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage is the most important independent prognostic variable for progression and overall survival for invasive bladder cancer. The standard staging system is the TNM (tumor, node, metastasis) system, which is based upon pathologic studies of cystectomy specimens (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"UTD.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/34\">",
"     34",
"    </a>",
"    ]. This staging system is applied to urothelial carcinoma, squamous cell carcinoma, undifferentiated carcinoma, and adenocarcinoma arising in the bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Tumor (T) stage",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ta lesions &mdash; Ta tumors are exophytic (papillary) lesions that tend to recur, but these are relatively benign and generally do not invade.",
"     </li>",
"     <li>",
"      Tis &mdash; Carcinoma in situ, or flat tumors.",
"     </li>",
"     <li>",
"      T1 lesions &mdash; If a tumor invades the submucosa or lamina propria, it is classified as a T1 tumor.",
"     </li>",
"     <li>",
"      T2 lesions &mdash; In T2 lesions, invasion into muscle is present. For T2 tumors, cystectomy is considered \"standard therapy\". When muscle invasion is present, the probability of nodal and distant metastases is increased. The 2010 TNM staging system divides muscle infiltrating (T2) disease into superficial (T2a) or deep (T2b) invasion, with disease still confined within the bladder [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T3 lesions &mdash; T3 tumors extend beyond muscle into the perivesical fat. CT or MRI scans may help to identify disease that has spread outside the bladder.",
"     </li>",
"     <li>",
"      T4 lesions &mdash; The TNM system differentiates tumors extending into adjacent organs (T4) from those extending into perivesical fat (T3). Tumor invading the prostate, vagina, uterus, or bowel is classified as T4a, while tumor fixed to the abdominal wall, pelvic wall, or other organs is T4b. Urothelial tumors may grow into the prostate, along the prostatic ducts; these are noninvasive lesions with a good prognosis when resected. Alternatively, they may directly invade the prostatic stroma, which indicates a worse prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most important prognostic determinant that is derived from staging is whether the tumor is organ-confined (&le;T2) or nonorgan-confined (&ge;T3). The accuracy of available methods for determining the degree of muscle invasiveness preoperatively is modest. Even in experienced hands, the correlation between depth of invasion, as assessed by cystoscopic evaluation and TURBT and the pathologic examination of the bladder at the time of cystectomy, is only about 70 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Nodal (N) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM system categorizes nodal disease based on the number and size of the involved nodes. It also accounts for metastases to specific sites.",
"   </p>",
"   <p>",
"    In the 2010 TNM staging system, a single lymph node metastasis in the true pelvis is considered N1 disease, multiple nodes in the true pelvis N2 disease, and nodal involvement of the common iliac nodes are classified as a secondary lymphatic drainage area (N3) rather than as metastatic disease. Lymph node sampling should include excision of an average of &gt;12 lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20217/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with nodal metastases but without disseminated disease may be treated with cystectomy or combined modality approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=see_link\">",
"     \"Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Metastatic (M) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of disseminated metastases (eg, lung, liver, bone) portends the need for systemic therapy. Despite significant advances, the long-term prognosis is poor for most patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=see_link\">",
"     \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=see_link\">",
"       \"Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/39/13939?source=see_link\">",
"       \"Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15205?source=see_link\">",
"       \"Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with urothelial bladder cancer typically present with painless hematuria, and the presence of unexplained hematuria in individuals over 40 years of age requires evaluation for a possible malignancy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cystoscopy is the initial procedure for both the diagnosis and management of urothelial malignancy. Cystoscopy is used to establish the diagnosis, assess whether or not muscle invasion is present, and provide initial therapy for non-muscle-invasive lesions. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cystoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urine cytology is widely used in combination with cystoscopy, to assess for the presence of carcinoma-in-situ and to evaluate for the presence of upper urinary tract lesions. Computed tomography the preferred imaging procedure to assess the local extent of disease and to further examine the renal pelvis and ureters. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Urine cytology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Urinary tract imaging'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=see_link\">",
"       \"Malignancies of the renal pelvis and ureter\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stage is the most important independent prognostic variable for assessing the probability of progression and survival. The standard approach is tumor node metastasis (TNM) staging system (",
"      <a class=\"graphic graphic_table graphicRef53395 \" href=\"UTD.htm?25/52/26445\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'TNM staging system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An overview of the treatment of bladder cancer is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2759?source=see_link\">",
"       \"Overview of the management of urothelial (transitional cell) bladder cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/1\">",
"      Wallace DM, Raghavan D, Kelly KA, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/2\">",
"      MARSHALL VF. Current clinical problems regarding bladder tumors. Cancer 1956; 9:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/3\">",
"      Khadra MH, Pickard RS, Charlton M, et al. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000; 163:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/4\">",
"      Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/5\">",
"      Mariani AJ, Mariani MC, Macchioni C, et al. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 1989; 141:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/6\">",
"      Grossfeld GD, Litwin MS, Wolf JS, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology 2001; 57:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/7\">",
"      Messing EM, Young TB, Hunt VB, et al. Home screening for hematuria: results of a multiclinic study. J Urol 1992; 148:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/8\">",
"      Mohr DN, Offord KP, Owen RA, Melton LJ 3rd. Asymptomatic microhematuria and urologic disease. A population-based study. JAMA 1986; 256:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/9\">",
"      Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/10\">",
"      Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/11\">",
"      Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005; 174:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/12\">",
"      Satoh E, Miyao N, Tachiki H, Fujisawa Y. Prediction of muscle invasion of bladder cancer by cystoscopy. Eur Urol 2002; 41:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/13\">",
"      Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/14\">",
"      Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/15\">",
"      Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/16\">",
"      Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/17\">",
"      Krieg RC, Messmann H, Rauch J, et al. Metabolic characterization of tumor cell-specific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells. Photochem Photobiol 2002; 76:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/18\">",
"      Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003; 61:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/19\">",
"      Gr&eacute;goire M, Fradet Y, Meyer F, et al. Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. J Urol 1997; 157:1660.",
"     </a>",
"    </li>",
"    <li>",
"     Karam JA, Shaj JB, Kader AK, et al. Prospective trial to identify optimal bladder cancer surveillance protocol: Reducing costs while maximizing sensitivity (abstract 275). Presented at the 2010 Genitourinary Cancers Symposium.",
"    </li>",
"    <li>",
"     Badalament RA, Ryan PR, Bahn DK. Imaging for transitional cell carcinomas. In: Comprehensive Textbook of Genitourinary Oncology, Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (Eds), Williams and Wilkins, Baltimore 2000. p.357.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/22\">",
"      Herr HW. Routine CT scan in cystectomy patients: does it change management? Urology 1996; 47:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/23\">",
"      JEWETT HJ, STRONG GH. Infiltrating carcinoma of the bladder; relation of depth of penetration of the bladder wall to incidence of local extension and metastases. J Urol 1946; 55:366.",
"     </a>",
"    </li>",
"    <li>",
"     Donat MD, Herr HW. Transitional cell carcinoma of the renal pelvis and ureter: diagnosis, staging, management, and prognosis. In: Urologic Oncology, Osterling JE, Richie JP (Eds), WB Saunders Harcourt Brace &amp; Co, Philadelphia 1997. p.215.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/25\">",
"      Tekes A, Kamel I, Imam K, et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol 2005; 184:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/26\">",
"      Kim B, Semelka RC, Ascher SM, et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994; 193:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/27\">",
"      Tachibana M, Baba S, Deguchi N, et al. Efficacy of gadolinium-diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging for differentiation between superficial and muscle-invasive tumor of the bladder: a comparative study with computerized tomography and transurethral ultrasonography. J Urol 1991; 145:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/28\">",
"      Tanimoto A, Yuasa Y, Imai Y, et al. Bladder tumor staging: comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT. Radiology 1992; 185:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/29\">",
"      Datta SN, Allen GM, Evans R, et al. Urinary tract ultrasonography in the evaluation of haematuria--a report of over 1,000 cases. Ann R Coll Surg Engl 2002; 84:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/30\">",
"      Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 2006; 36:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/31\">",
"      Drieskens O, Oyen R, Van Poppel H, et al. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005; 32:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/32\">",
"      Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009; 27:4314.",
"     </a>",
"    </li>",
"    <li>",
"     Apolo AB, Riches J, Boyle MG, et al. Clinical value of 18F-2-deoyglucose positron emission tomography (FDG PET) in bladder cancer (abstract). Presented at the 2009 Genitourinary Cancers Symposium.",
"    </li>",
"    <li>",
"     Urinary bladder. In: AJCC Cancer Staging Manual, 7th, Springer, New York 2010. p.497.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20217/abstract/35\">",
"      Herr HW, Donat SM. Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome. J Urol 1999; 161:1854.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2989 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20217=[""].join("\n");
var outline_f19_47_20217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Voiding symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Constitutional symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cystoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fluorescence cystoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Urine cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Urine-based markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Urinary tract imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - CT scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Intravenous pyelogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Imaging for metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Lung lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Bone scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - PET",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      HISTOLOGIC GRADE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TNM STAGING SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Tumor (T) stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Nodal (N) disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Metastatic (M) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2989\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2989|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/42/15011\" title=\"diagnostic image 1\">",
"      CT locally advanced bladder CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/52/6976\" title=\"diagnostic image 2\">",
"      Bladder tumor cystogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/8/2191\" title=\"diagnostic image 3\">",
"      IVP renal pelvic tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/22/1377\" title=\"diagnostic image 4\">",
"      IVP distal ureteral tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2989|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/52/26445\" title=\"table 1\">",
"      TNM staging bladder CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=related_link\">",
"      Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2759?source=related_link\">",
"      Overview of the management of urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27481?source=related_link\">",
"      Pathology of bladder neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=related_link\">",
"      Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15205?source=related_link\">",
"      Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/39/13939?source=related_link\">",
"      Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=related_link\">",
"      Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=related_link\">",
"      Treatment of metastatic urothelial cancer of the bladder and urinary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=related_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32298?source=related_link\">",
"      Urinary diversion and reconstruction following cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40041?source=related_link\">",
"      Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_47_20218="Choice of therapy in essential hypertension: Clinical trials";
var content_f19_47_20218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Choice of therapy in essential hypertension: Clinical trials",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20218/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20218/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20218/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20218/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/47/20218/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/47/20218/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/47/20218/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 7, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although recommendations for initiating medical therapy in essential hypertension have been proposed (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    ), there is no uniform agreement on which antihypertensive agent should be given for initial therapy. A variety of different classes of drugs can be used in this setting. These include the thiazide diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, calcium channel blockers, and beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of different antihypertensive agents and a review of some of the clinical trials that examined their effects upon patient outcomes, particularly cardiovascular morbidity and mortality, will be presented here. Recommendations concerning the use of particular agents in specific patients, and the evidence supporting the value of treating different degrees of hypertension are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice among the different antihypertensive drugs has NOT generally been made on the basis of efficacy, since each of the first-line drugs is roughly equally effective and thereby has provided similar reductions for most cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/1-3,5\">",
"     1-3,5",
"    </a>",
"    ]. There is, however, wide interpatient variability as many patients will respond well to one drug but not to another. In one cross-over study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , for example, there was no predictable relationship between the fall in blood pressure seen with the two drugs: good responses were seen with both, neither, or only one of the drugs in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, efforts have been made to find factors that might predict a preferential response to a particular class. One controlled trial evaluated the efficacy of monotherapy with six different antihypertensive drugs in almost 1300 men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/3\">",
"     3",
"    </a>",
"    ]. These patients had initial diastolic pressures between 95 and 109 mmHg and a successful response was defined as a fall in diastolic pressure to below 95 mmHg at one year. The following findings were noted at one year:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The highest overall response rate was seen with the calcium channel blocker",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , but this benefit became apparent only at the highest dose.",
"     </li>",
"     <li>",
"      The differential response was most prominent in blacks. Older black patients responded best to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      , while younger blacks (less than 60 years of age) responded best to diltiazem.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       Captopril",
"      </a>",
"      was least effective in both groups (",
"      <a class=\"graphic graphic_figure graphicRef65117 \" href=\"UTD.htm?37/22/38253\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=see_link\">",
"       \"Treatment of hypertension in blacks\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There were fewer differences between the drugs in non-black patients who tended to respond roughly equally to each of the different drugs. One exception was that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      was least effective in younger whites (",
"      <a class=\"graphic graphic_figure graphicRef77960 \" href=\"UTD.htm?2/36/2638\">",
"       figure 2",
"      </a>",
"      ). The relative lack of a hierarchy of response also seems to apply to Hispanic and Asian Americans [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There were no significant differences in side effects or quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were reported in the Treatment of Mild Hypertension Study (TOMHS). This trial evaluated five different first-line drugs combined with dietary modification to dietary modification alone in a population that was largely non-black [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/2\">",
"     2",
"    </a>",
"    ]. There were no significant differences in efficacy, although the percent of patients controlled with monotherapy was highest with the calcium channel blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    . The incidence of side effects was similar with the different drugs, but the thiazide diuretic was associated with a higher frequency of erectile dysfunction (17.1 versus 8.1 percent with placebo). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of male sexual dysfunction\", section on 'Sexual history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A third study of 56 hypertensive patients evaluated the efficacy of a crossover rotation of four classes of antihypertensive drugs: an ACE inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    or drug A), a beta-blocker (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    or drug B), a calcium-channel blocker (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    or drug C), and a diuretic ([",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    ] or drug D) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/8\">",
"     8",
"    </a>",
"    ]; 36 patients received all four monthly cycles of each drug administered as monotherapy. The variability in response was assessed by comparing the best antihypertensive response to that obtained with the first administered drug, and by attempting to correlate the response of each drug to the other drugs. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately one-half of patients who achieved the target blood pressure of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg did not obtain such readings with the first assigned agent.",
"     </li>",
"     <li>",
"      The rotation schedule increased the rate of success of monotherapy (from 39 to 73 percent, p = 0.0001).",
"     </li>",
"     <li>",
"      Significant correlations were observed between the response to drug A (ACE inhibitor) and that to drug B (beta-blocker) as well as the responses to drugs C (calcium channel blocker) and D (diuretic); by comparison, no correlations were observed between the other pairings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of these trials, the British Hypertension Society (BHS) recommended that an \"A\" drug (an ACE inhibitor or ARB) be chosen for initial therapy for younger (less than 55 years of age) and non-black patients, whereas a \"C\" (calcium channel blocker) or a \"D\" (diuretic) be chosen for the elderly and black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/9\">",
"     9",
"    </a>",
"    ]. The original BHS algorithm included a beta-blocker \"B\" for the younger and non-black, but on the basis of evidence that beta-blockers were less protective against stroke than other classes of drugs despite equal antihypertensive efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/10\">",
"     10",
"    </a>",
"    ], the \"B\" choice was deleted [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The variable responses of such patients to the various drugs may reflect their different levels of angiotensin-renin, as measured by plasma renin activity (PRA). PRA is usually higher in younger and non-black patients (who would therefore have a greater response to an \"A\" drug), and is usually lower in the older and black patients (who have a lesser response to an \"A\" drug but better response to a \"C\" or \"D\" drug).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DOES THE CHOICE OF DRUG AFFECT OUTCOME?",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increasing number of trials have provided evidence that, at the same level of blood pressure control, most antihypertensive drugs provide the same degree of cardiovascular protection, particularly cardiovascular morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]. There may be some differences in selected outcomes, such as stroke, or in noncardiovascular outcomes such as the development of diabetes, and differences based on patient characteristics, such as presence of diabetes and race.",
"   </p>",
"   <p>",
"    These observations led to a general consensus, including 2007 guidelines from the American Heart Association [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/12\">",
"     12",
"    </a>",
"    ] and the 2009 revision of the 2007 European Society of",
"    <span class=\"nowrap\">",
"     Hypertension/European",
"    </span>",
"    Society of Cardiology guidelines, that the amount of BP reduction is the major determinant of reduction in cardiovascular risk, not the choice of antihypertensive drug [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'ACCOMPLISH trial'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H28#H28\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     MRC trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Medical Research Council trial of middle-aged subjects with mild to moderate hypertension (diastolic pressure 90 to 109 mmHg) found no overall difference in outcome between a thiazide diuretic and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , both of which were more effective than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A later MRC trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    to the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    (25 to 50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    or placebo in elderly hypertensive subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/16\">",
"     16",
"    </a>",
"    ]. In these trials, beta blockers reduced the incidence of cerebrovascular disease but not coronary events or cardiovascular or all-cause mortality; in comparison, diuretic therapy was associated with improvement in all of these end points [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. A meta-analysis of comparative trials using beta-blockers for primary protection found them to be less effective than other classes in protecting against stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     CAPPP trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the CAPPP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     Captopril",
"    </a>",
"    Prevention Project) trial, 10,985 patients between the ages of 25 and 66 with a diastolic blood pressure of at least 100 mmHg were randomly assigned to captopril (given once or twice per day, up to 100",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    or to conventional therapy (a beta blocker",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a diuretic) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/18\">",
"     18",
"    </a>",
"    ]. The principal end points were fatal and nonfatal myocardial infarction, stroke, and other cardiovascular deaths. Since the randomized groups differed, statistical analysis corrected relative imbalances, such as a slight difference in entry blood pressure. At follow-up at six years, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No difference was observed in the risk of a cardiovascular event between the two treatment groups.",
"     </li>",
"     <li>",
"      A mild increase in the risk of stroke was observed in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      group, although no difference was found in the incidence of fatal stroke. This enhanced risk was attributed to the lower blood pressure attained in previously treated patients in the conventional therapy group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, subsequent subgroup analysis found that diabetic patients randomized to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    had a 40 percent reduction in the relative risk of all primary end points [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     STOP Hypertension 2 trial and NORDIL trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same conclusion, that newer and older drugs generally provide similar benefit, was reached in the STOP-Hypertension-2 trial and the Nordic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    (NORDIL) trial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the STOP-Hypertension-2 trial, 6614 elderly patients (age 70 to 84) with a systolic pressure &ge;180 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a diastolic pressure &ge;105 mmHg were randomly assigned to one of three treatment groups: conventional therapy with a beta blocker or diuretic; an ACE inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      ), or a dihydropyridine calcium channel blocker (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"       felodipine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=see_link\">",
"       isradipine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/20\">",
"       20",
"      </a>",
"      ]. The degree of blood pressure control",
"      <span class=\"nowrap\">",
"       (194/98",
"      </span>",
"      at baseline to",
"      <span class=\"nowrap\">",
"       159/81)",
"      </span>",
"      and, at 4.5 year follow-up, the combined end point of fatal and nonfatal stroke or myocardial infarction and other cardiovascular mortality were the same in the three groups.",
"     </li>",
"     <li>",
"      The NORDIL trial randomly assigned nearly 11,000 patients with a diastolic blood pressure of &ge;100 mmHg to a regimen consisting of diuretics, beta blockers, or both, or to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/21\">",
"       21",
"      </a>",
"      ]. The combined primary end point of stroke (fatal and non-fatal), myocardial infarction, and other cardiovascular death occurred in almost exactly the same number of patients in both populations (403 and 400 patients in the diltiazem and conventional therapy groups, respectively). Although subset analysis suggested that diltiazem provided significantly better protection against stroke, this benefit may have been due to chance given the number of statistical comparisons performed in this study. An alternate explanation is that the lesser protection from stroke resulted from the 3 mmHg higher systolic pressure in those on conventional therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     INSIGHT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding from the STOP-Hypertension-2 and NORDIL studies that calcium channel blockers provide equivalent cardiovascular benefit to that of older antihypertensive regimens appears to extend to patients at high-risk of an adverse cardiovascular outcome. In the Intervention as a Goal in Hypertension Treatment (INSIGHT) study, over 6000 patients with hypertension and at least one additional cardiovascular risk factor were randomly assigned to long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    GTS or to co-amilozide (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    [25 to 50",
"    <span class=\"nowrap\">",
"     mg/day]",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both regimens resulted in an equivalent degree of blood pressure control. The number of patients in whom a primary outcome (defined as cardiovascular death, myocardial infarction, heart failure, or stroke) occurred was similar in both randomized groups (200 and 182 in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and co-amilozide groups, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     ALLHAT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the STOP Hypertension 2, NORDIL, CAPPP, and INSIGHT and INVEST trials, the ALLHAT trial generally found that an older antihypertensive agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    (a thiazide diuretic), and newer agents provided similar cardiovascular protection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/23\">",
"     23",
"    </a>",
"    ]. The ALLHAT trial will be reviewed in detail here. Issues related to the lipid lowering aspect of this trial are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ALLHAT was a randomized prospective trial of nearly 45,000 patients with hypertension (mean blood pressure",
"    <span class=\"nowrap\">",
"     146/84",
"    </span>",
"    mmHg) and at least one additional risk factor for coronary heart disease, such as previous myocardial infarction or stroke (greater than six months before), left ventricular hypertrophy, type 2 diabetes, current cigarette smoking, HDL cholesterol level less than 35",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.91",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    or atherosclerotic cardiovascular disease.",
"   </p>",
"   <p>",
"    ALLHAT was designed to evaluate whether the incidence of adverse cardiovascular outcomes differed among those randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    (12.5 to a maximum of 25",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    the equivalent dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    is 1.5 to 2.0 times higher) compared to one of three other antihypertensive drugs:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    (a calcium channel blocker),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    (an ACE inhibitor), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    (an alpha-adrenergic blocker). The doxazosin arm was terminated prematurely because of a significantly increased risk of heart failure compared to chlorthalidone (relative risk 2.0 after adjusting for a 3 mmHg higher in-trial systolic pressure with doxazosin) noted during an interim analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The baseline characteristics of the patients in the remaining three treatment groups were similar, including the presence of relatively mild hypertension (initial mean untreated and treated blood pressures being approximately",
"    <span class=\"nowrap\">",
"     156/89",
"    </span>",
"    mmHg and",
"    <span class=\"nowrap\">",
"     145/83",
"    </span>",
"    mmHg, respectively).",
"   </p>",
"   <p>",
"    At a mean follow-up of almost five years, each of the antihypertensive agents successfully lowered blood pressure. However, compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    , the mean systolic blood pressure was slightly higher with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    , while the mean diastolic blood pressure was lower with amlodipine",
"    <span class=\"nowrap\">",
"     (133.9/75.4,",
"    </span>",
"    <span class=\"nowrap\">",
"     134.7/74.6,",
"    </span>",
"    <span class=\"nowrap\">",
"     135.9/75.4",
"    </span>",
"    mmHg for chlorthalidone, amlodipine and lisinopril, respectively).",
"   </p>",
"   <p>",
"    With respect to clinical outcomes, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of the primary outcome (fatal coronary heart disease and nonfatal myocardial infarction), and all-cause mortality were the",
"      <strong>",
"       same",
"      </strong>",
"      for all three agents (",
"      <a class=\"graphic graphic_figure graphicRef82432 \" href=\"UTD.htm?6/63/7166\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A higher rate of heart failure was observed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      (10.2 versus 7.7 percent, RR 1.38, 95% CI 1.25-1.52) (",
"      <a class=\"graphic graphic_figure graphicRef68780 \" href=\"UTD.htm?39/59/40893\">",
"       figure 4",
"      </a>",
"      ). The other secondary outcomes were the same in both arms.",
"     </li>",
"     <li>",
"      Compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      had",
"      <strong>",
"       higher",
"      </strong>",
"      rates of combined cardiovascular disease outcomes (33.3 versus 30.9 percent, RR 1.10), heart failure (8.7 versus 7.7 percent, RR 1.19) (",
"      <a class=\"graphic graphic_figure graphicRef68780 \" href=\"UTD.htm?39/59/40893\">",
"       figure 4",
"      </a>",
"      ), and stroke (6.3 versus 5.6 percent, RR 1.15) (",
"      <a class=\"graphic graphic_figure graphicRef61612 \" href=\"UTD.htm?39/18/40237\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations were observed consistently across practically all subgroups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The conclusions relating to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      were true for men, women, blacks, non-blacks, diabetics and nondiabetic patients, younger and older individuals and, as shown in a post hoc analysis, patients with metabolic syndrome (",
"      <a class=\"graphic graphic_figure graphicRef62097 \" href=\"UTD.htm?15/52/16206\">",
"       figure 6",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The results with respect to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      were generally consistent across gender, age, and diabetic status, although there were a few outcome differences among subgroups (",
"      <a class=\"graphic graphic_figure graphicRef52700 \" href=\"UTD.htm?14/60/15310\">",
"       figure 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef70843 \" href=\"UTD.htm?15/45/16094\">",
"       figure 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50881 \" href=\"UTD.htm?15/34/15918\">",
"       figure 9",
"      </a>",
"      ). As an example, the risks of stroke and combined cardiovascular disease among blacks given lisinopril were higher than among blacks given the diuretic (RR of 1.40 and 1.19, respectively); a similar result was seen among nondiabetic patients and patients who had metabolic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two specific adverse biochemical changes were associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypokalemia occurred in 8.5 percent (versus 1.9 and 0.8 percent for the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      groups, respectively), requiring potassium supplementation in approximately 8 percent.",
"     </li>",
"     <li>",
"      Among nondiabetic patients, a significantly more frequent elevation in fasting glucose to values &ge;126",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      which is a diagnostic criterion for type 2 diabetes (11.6 versus 9.8 and 8.1 percent for the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      groups, respectively). The mean increase in fasting glucose level was higher with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      versus amlodipine and lisinopril (+8.5, +5.5 and +3.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [0.47,0.31, and 0.19",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A reanalysis of these data revealed that the higher risk of heart failure associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    , versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    , was greatest in the first year (RR 2.24, 95% CI 1.68-2.98 and 2.08, 95% CI 1.56-2.78, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk was greatly attenuated after the first year (RR 1.24, 95% CI 1.01-1.41 and 0.97, 95% CI 0.85-1.11, for amlodipine and lisinopril, respectively, versus chlorthalidone). However, throughout the period of observation, the unadjusted risk of hospitalized or fatal heart failure remained higher for the amlodipine group compared with those treated with chlorthalidone (RR 1.35, 95% CI 1.21-1.50) and lisinopril (RR 1.23, 95% CI 1.09-1.38). There was no difference in this outcome between the lisinopril and chlorthalidone groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Summary of ALLHAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal finding of ALLHAT is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    provided similar protection from coronary heart disease death and nonfatal myocardial infarction among patients with hypertension and risk factors for cardiovascular disease, a result consistent with CAPPP, STOP Hypertension 2, and other trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, amlodipine, a calcium channel blocker, was not associated with an excess number of cardiac deaths, which had been a concern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike the smaller trials previously reviewed, the large number of participants in ALLHAT provided the power to detect that a thiazide diuretic may actually be superior to a calcium channel blocker and an ACE inhibitor in preventing some adverse cardiovascular outcomes. Development of heart failure, for example, was significantly less common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    than with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    , but this effect was attenuated after the first year. Some of these benefits with chlorthalidone are consistent with findings from other studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increased risk of stroke and combined cardiovascular disease among blacks given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      is consistent with the observation in most studies that ACE inhibitors may be relatively less effective in blacks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=see_link\">",
"       \"Treatment of hypertension in blacks\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The higher rate of new onset heart failure with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      is consistent with trends observed in some other trials [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Somewhat surprising, however, is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    failed to provide an advantage for any outcome measure compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    . To the contrary, lisinopril had higher rates than chlorthalidone of combined cardiovascular disease outcomes, stroke (",
"    <a class=\"graphic graphic_figure graphicRef61612 \" href=\"UTD.htm?39/18/40237\">",
"     figure 5",
"    </a>",
"    ), and heart failure (",
"    <a class=\"graphic graphic_figure graphicRef68780 \" href=\"UTD.htm?39/59/40893\">",
"     figure 4",
"    </a>",
"    ). Chlorthalidone was also superior to lisinopril among diabetic patients in preventing new onset heart failure and the combined cardiovascular disease outcome.",
"   </p>",
"   <p>",
"    One possible explanation for this unexpected result is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    provided relatively less blood pressure control than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    , as the first two years of the trial were associated with a 3 to 4 mmHg higher blood pressure with the ACE inhibitor. Additional possibilities include handicapping of the lisinopril arm because of inappropriate add-on therapy (eg, beta blockers), use in African-Americans, and confounding due to a significant number of participants discontinuing randomized study drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the better protection found with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    has been the most commonly used diuretic drug, at least in the United States. At the same dose, chlorthalidone is 1.5 to 2.0 times as potent as hydrochlorothiazide and is longer acting. Thus, 12.5 to 25 mg of hydrochlorothiazide, which is the most common thiazide regimen for the treatment of essential hypertension, is NOT the equivalent to 12.5 to 25 mg of chlorthalidone, the dose used in ALLHAT. As a result, hydrochlorothiazide may not provide the same benefits as seen with chlorthalidone in ALLHAT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H5#H5\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Chlorthalidone versus hydrochlorothiazide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     ANBP2 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Second Australian National Blood Pressure (ANBP2) study directly compared outcomes with an ACE inhibitor and a diuretic among elderly patients with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/33\">",
"     33",
"    </a>",
"    ]. Some of the results appear, at first glance, to directly contradict those of ALLHAT, as ACE inhibitors provided some superior cardiovascular outcomes. Possible reasons for these findings are discussed in the summary for this section.",
"   </p>",
"   <p>",
"    ANBP2 was a prospective study of 6083 elderly hypertensive patients (aged 65 to 84 years of age) who were randomly assigned to an antihypertensive regimen based upon either an ACE inhibitor (with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    recommended) or a diuretic (with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    recommended). The primary end point was all cardiovascular events, including initial and subsequent events, or death from any cause. Events included coronary events (such as myocardial infarction, sudden death from cardiac causes, and others), other cardiovascular outcomes (such as heart failure, death from vascular causes, and others), and cerebrovascular events (such as stroke and transient ischemic attacks).",
"   </p>",
"   <p>",
"    The mean initial blood pressures were the same for the ACE inhibitor and diuretic groups",
"    <span class=\"nowrap\">",
"     (167/91",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     168/91",
"    </span>",
"    mmHg, respectively). The therapeutic goals were a reduction in systolic pressure of at least 20 mmHg to less than 160 mmHg and preferably to less than 140 mmHg, if tolerated; the diastolic goal was a fall of at least 10 mmHg to less than 90 mmHg and preferably to less than 80 mmHg, if tolerated.",
"   </p>",
"   <p>",
"    Similar office blood pressure control was observed in both arms. At study end at a median of 4.1 years, office blood pressure had decreased by",
"    <span class=\"nowrap\">",
"     26/12",
"    </span>",
"    mmHg in both groups. To achieve this, 65 and 67 percent of the patients in the ACE inhibitor and diuretic arms were receiving monotherapy, respectively, with the remainder being given two or more agents.",
"   </p>",
"   <p>",
"    The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ACE inhibitor group had a",
"      <strong>",
"       lower",
"      </strong>",
"      incidence of the primary end point (eg, all cardiovascular events or death from any cause) compared with the diuretic group (hazard ratio of 0.89, 95% CI 0.79-1.00). The benefit was due to a decrease in the rate of nonfatal events with ACE inhibitors, as there was no mortality difference between the two groups.",
"     </li>",
"     <li>",
"      The benefits with ACE inhibitor therapy were restricted to men, as the hazard ratios for the primary end point were 0.83 (95% CI 0.71-0.97) and 1.00 (95% CI 0.83-1.21) for men and women, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Summary of ANBP2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ANBP2 study found that antihypertensive therapy based upon ACE inhibitors, compared with diuretics, appeared to provide a superior benefit in some cardiovascular outcomes in elderly men. This result differs from that of ALLHAT, which reported that diuretics were more effective than ACE inhibitors.",
"   </p>",
"   <p>",
"    Possible reasons for the apparently contradictory results from ANBP2 and ALLHAT include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient populations were different. Criteria for inclusion in ANBP2 did not specifically require additional risk factors for heart disease, unlike ALLHAT. In addition, the pretreatment blood pressures in ANBP2 were higher, and the enrolled patient population was almost all non-black (approximately 95 percent versus 65 percent in ALLHAT) and much older (mean age 76 versus 61 years).",
"     </li>",
"     <li>",
"      ANBP2 was an open label-study, potentially biasing the reporting of events [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients in ALLHAT received the specific study drug in each assigned class, administered within certain dose ranges. By comparison, in ANBP2, the antihypertensive agent within each class and dose were chosen by the individual physician, although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      were recommended for initial therapy. The possible use of high doses of thiazides in ANBP2, which are associated with adverse cardiovascular outcomes, may have contributed to the relatively greater benefits observed with ACE inhibitors.",
"     </li>",
"     <li>",
"      The primary outcomes of each study were different. In ANBP2 it was the total number of fatal and nonfatal cardiovascular events (which favored the ACE inhibitor), whereas in ALLHAT, it was death from coronary causes or nonfatal myocardial infarction (which was similar for all study arms). By comparison, diuretic-based therapy was superior in ALLHAT in terms of a few secondary outcomes (eg, new onset heart failure). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'ALLHAT trial'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     INVEST trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;INVEST was an international multicenter trial of over 22,556 hypertensive patients (mean baseline pressure",
"    <span class=\"nowrap\">",
"     150/86",
"    </span>",
"    mmHg) with known coronary artery disease that was designed to compare the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    (initial dose 240",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of the sustained release formulation, which could be increased to a maximum of 180 mg twice daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    (initial dose 50",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    which could be increased to a maximum of 50 mg twice daily) in reducing cardiovascular morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients were randomly assigned to either drug, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"     trandolapril",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    added as needed to achieve blood pressure control. Each of the additional agents was used by approximately 50 percent or more of the patients in each arm. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Achieved mean systolic and diastolic blood pressures were identical in both groups throughout the 48 months of follow-up.",
"     </li>",
"     <li>",
"      There was no difference between the groups in the incidence of the combined primary outcome (death, nonfatal myocardial infarction or nonfatal stroke), nor any of the secondary outcomes (individual components of the primary outcome, cardiovascular death, cardiovascular hospitalizations, angina or stroke).",
"     </li>",
"     <li>",
"      No significant differences were noted in subgroups analyses (age, gender, race, diabetic status).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study also found that the combination of a nondihydropyridine calcium channel blocker plus an ACE inhibitor lowered the risk of developing or worsening diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/37\">",
"     37",
"    </a>",
"    ] and that consistent blood pressure control with either agent improved cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ASCOT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    -based therapy provided less cardiovascular benefit than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    -based therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The blood pressure lowering aspect of the ASCOT trial will be reviewed in detail here. A full description of the study, including inclusion and exclusion criteria, and results related to lipid lowering are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'ASCOT-LLA trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ASCOT trial was a randomized controlled prospective trial of 19,342 hypertensive patients with at least three risk factors for coronary heart disease (CHD) who were assigned to receive one of two antihypertensive regimens. Patients were defined as hypertensive if untreated systolic blood pressure was 160 mmHg or greater",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic blood pressure was 100 mmHg or greater, or if blood pressure was",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg or greater on treatment. The mean baseline blood pressure was",
"    <span class=\"nowrap\">",
"     164/95",
"    </span>",
"    mmHg.",
"   </p>",
"   <p>",
"    The study was designed to determine whether the incidence of adverse cardiovascular outcomes differed if blood pressure was treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    5 mg (plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    if needed) compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    50 mg (and bendroflumethiazide if needed). The goal blood pressure was",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg or lower for nondiabetic and diabetic patients, respectively, with a designated treatment algorithm to escalate dose and add medications as needed to achieve goal blood pressure.",
"   </p>",
"   <p>",
"    The combined primary outcome was fatal coronary events and nonfatal MI, while the secondary outcomes were all-cause mortality, stroke, all coronary events, total cardiovascular disease events and procedures, and nonfatal and fatal heart failure.",
"   </p>",
"   <p>",
"    The trial was prematurely stopped after a median of 5.5 years due to worse outcomes in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    -treated group. Compared with atenolol (plus a thiazide in 49 percent by the end of the first year and 56 percent by the end of the study),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    (plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    in 39 percent by the end of the first year and 54 percent by the end of the study) was associated with [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fewer nonfatal MIs and fatal coronary events (8.2 versus 9.1 per 1000 patient-years; RR 0.90), fewer fatal and nonfatal strokes (6.2 versus 8.1 per 1000 patient-years; RR 0.77) and fewer total cardiovascular events and procedures (27.4 versus 32.8 per 1000 patient-years; RR 0.84)",
"     </li>",
"     <li>",
"      A lower rate of all cause mortality (13.9 versus 15.5 per 1000 patient-years; RR 0.89).",
"     </li>",
"     <li>",
"      A lower rate of developing diabetes (11.0 versus 15.9 per 1000 patient-years; RR 0.70), which has been noted with ACE inhibitors in multiple other studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H30#H30\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Inhibition of angiotensin II'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was no significant difference in subgroups stratified by gender, age, or presence or absence of diabetes, smoking, left ventricular hypertrophy, renal dysfunction, previous vascular disease, metabolic syndrome or baseline heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/40\">",
"     40",
"    </a>",
"    ]. As in most trials, goal blood pressure was achieved in only a fraction of patients (32 and 60 percent of the diabetic and nondiabetic patients).",
"   </p>",
"   <p>",
"    Possible factors that could contribute to these differences in outcomes include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean blood pressure at the end of the study was slightly lower in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      group than in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      group, with a mean difference throughout the study of",
"      <span class=\"nowrap\">",
"       3/2",
"      </span>",
"      mmHg. This may in part be related to the use of atenolol once daily, since its pharmacokinetic profile favors twice daily use. In INVEST, where atenolol was given twice daily, the blood pressure reduction and efficacy compared to a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      -based regimen were identical. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'INVEST trial'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In addition, it is possible that the degree of blood pressure reduction achieved by beta blockers is overestimated when blood pressure is measured by standard cuff techniques. By contrast blood pressure reduction achieved by the use of diuretics, calcium channel blockers or ACE inhibitors is accurately reflected by brachial cuff pressure as compared to central aortic pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/42-44\">",
"       42-44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      It was estimated that the difference in blood pressure could account for approximately one-half of the difference in outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/40\">",
"       40",
"      </a>",
"      ]. When adjustment was made for other covariates, the difference in outcomes was no longer significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Summary of ASCOT",
"    </span>",
"    &nbsp;&mdash;&nbsp;ASCOT found a lower rate of cardiovascular disease and mortality with an antihypertensive regimen based upon",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    compared to a regimen based upon",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    in patients with no active cardiovascular disease; however, the difference in blood pressure reduction and other covariates may account for most of the apparent benefit from amlodipine. In the INVEST trial of a different population, regimens based upon",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and atenolol resulted in similar blood pressure reductions and outcomes. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'INVEST trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     ONTARGET trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ONTARGET trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    and combination therapy with both agents in 25,620 patients with vascular disease or diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The primary outcome was death from cardiovascular causes, myocardial infarction, stroke or hospitalization for heart failure. Although the achieved mean blood pressure was lower in patients who received telmisartan or both agents compared to ramipril alone, there was no difference in the composite primary outcome in the three groups (16.7 and 16.5 versus 16.3 percent with combined therapy [relative risk 0.99]).",
"   </p>",
"   <p>",
"    Side effects including cough and angioedema were reported more frequently with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"     telmisartan",
"    </a>",
"    , while hypotension and renal dysfunction were more common with telmisartan. Patients treated with combined therapy had a higher rate of adverse events than those receiving monotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H18#H18\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Combination of ACE inhibitors and ARBs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     ACCOMPLISH trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the above trials compared different classes of antihypertensive drugs. The ACCOMPLISH trial is the first major trial addressing the issue of combination therapy in 11,506 patients who were at high cardiovascular risk (defined as prior cardiovascular disease, diabetes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired renal function) and, despite prior antihypertensive therapy in 97 percent, had a mean baseline blood pressure of",
"    <span class=\"nowrap\">",
"     145/80",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The goal blood pressure was less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg in the patients with diabetes or impaired renal function and less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg in the patients with prior cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patients were randomly assigned (without a washout period) to combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    (12.5",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Benazepril was increased to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in both groups at one month. If goal blood pressure was not attained, the amlodipine dose was increased to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and the hydrochlorothiazide dose to 25",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The addition of beta blockers, alpha blockers, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    was permitted if the blood pressure remained above goal.",
"   </p>",
"   <p>",
"    The primary end point was measured as the time to the first event, which was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac death and coronary revascularization. The trial was terminated early at a mean follow-up of 36 months when the prespecified stopping rule was exceeded. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary end point was achieved significantly less often in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/19/16696?source=see_link\">",
"       benazepril",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      group (9.6 versus 11.8 percent, hazard ratio 0.80, 95% CI 0.72-0.90). There was a similar greater benefit with benazepril-amlodipine in the secondary end point of cardiovascular death (hazard ratio 0.79).",
"     </li>",
"     <li>",
"      The mean blood pressure was slightly (about 1 mmHg) but significantly lower in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/19/16696?source=see_link\">",
"       benazepril",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      group",
"      <span class=\"nowrap\">",
"       (131.6/73.3",
"      </span>",
"      compared to",
"      <span class=\"nowrap\">",
"       132.5/74.4",
"      </span>",
"      mmHg). In contrast, 24-hour blood pressure monitoring in a subset of 573 patients in ACCOMPLISH revealed a nonsignificant",
"      <span class=\"nowrap\">",
"       1.6/0.3",
"      </span>",
"      mmHg higher 24-hour average blood pressure in the benazepril-amlodipine group [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/49\">",
"       49",
"      </a>",
"      ]. Similar trends were noted with daytime and nighttime average blood pressures. Thus, the clinical benefits with the benazepril-amlodipine combination cannot be explained by better blood pressure control.",
"     </li>",
"     <li>",
"      The frequency of discontinuation of study drug because of adverse events was similar in the two groups (28.8 versus 31.2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Beta blockers as initial therapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether beta blockers offer the same degree of cardiovascular protection as other antihypertensive drugs in patients with essential hypertension who have no specific indications for their use (eg, resting tachycardia, angina pectoris, or a recent myocardial infarction). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H17#H17\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Indications for specific drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few early studies suggested that beta blockers might reduce the incidence of coronary disease in hypertensive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. However, later trials demonstrated either a similar cardioprotective effect with beta blockers (mostly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ) compared to other antihypertensive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/18,52,53\">",
"     18,52,53",
"    </a>",
"    ] or worse outcomes with beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/15-17,54,55\">",
"     15-17,54,55",
"    </a>",
"    ]. Furthermore, trials have suggested that conventional but not vasodilating beta blockers increase the risk of developing type 2 diabetes mellitus or decreased insulin sensitivity in diabetic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an attempt to resolve these conflicting findings regarding cardiovascular protection, a number of meta-analyses have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/5,10,56-58\">",
"     5,10,56-58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One meta-analysis compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      with other antihypertensive drugs (five trials with 17,671 participants) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/56\">",
"       56",
"      </a>",
"      ]. Atenolol was associated with a significantly increased risk of all-cause mortality and stroke (relative risk 1.13 and 1.30, respectively). It is unclear whether conclusions regarding atenolol can be extended to all beta blockers, since atenolol (particularly once daily dosing) may not provide adequate blood pressure control [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent meta-analysis of 13 trials (105,951 participants, with ASCOT and CONVINCE comprising one-third of all participants) included trials using a variety of beta blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/10\">",
"       10",
"      </a>",
"      ]. When trials with any beta blocker (mostly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      ) were examined, beta blockers were associated with an increased risk of stroke compared to other agents. The MRC trial of 8700 patients, by far the largest trial evaluating non-atenolol beta blockers, compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      to a thiazide diuretic or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/15\">",
"       15",
"      </a>",
"      ]. Propranolol was associated with a significant increase in stroke compared to the thiazide (1.0 versus 0.4 percent, relative risk 2.3, 95% CI 1.3-3.9) due mostly to an increase in risk among smokers. The stroke rate with propranolol was lower than in the placebo group. Myocardial infarction and all-cause mortality were not significantly different between the groups.",
"     </li>",
"     <li>",
"      A meta-analysis using many of the same trials found that the increased risk of stroke with beta blockers was limited to patients &ge;60 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A more inclusive meta-analysis that included 147 trials [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/5\">",
"       5",
"      </a>",
"      ], showed an 18 percent lower primary protection against stroke than reported by a previous meta-analysis of 15 trials, in which a beta-blocker was used as initial therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/10\">",
"       10",
"      </a>",
"      ]. The larger meta-analysis confirmed a significant benefit of beta-blockers when used as secondary protection after an acute myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in the absence of a specific indication for their use, we and others suggest that beta blockers NOT be used as primary therapy for hypertension, particularly in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/9,17,57,60\">",
"     9,17,57,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Trials in specific subgroups",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     HYVET trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of treating hypertension in patients over age 80 was directly addressed in the Hypertension in the Very Elderly Trial (HYVET) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/61\">",
"     61",
"    </a>",
"    ]. In HYVET, 3845 hypertensive patients over age 80 were randomly assigned to either a placebo or active therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35846?source=see_link\">",
"     indapamide",
"    </a>",
"    with or without the ACE inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    . At 1.8 years, active therapy was associated with 21, 30 and 64 percent reductions in total mortality, strokes and heart failure. A full discussion of this trial can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'HYVET trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     High cardiovascular risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of blood pressure reduction and, in some cases, different antihypertensive drugs, in patients at high cardiovascular risk has been investigated in several major clinical trials. The trials that addressed this issue include ALLHAT, VALUE, CAMELOT, and ACCOMPLISH. Based upon trial design, inclusion criteria, and patient population, the degree of blood pressure lowering varied significantly in these trials. ALLHAT and ACCOMPLISH are described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     LIFE trial of severe LVH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LIFE trial evaluated the specific cardiovascular benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    in high-risk patients with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/55\">",
"     55",
"    </a>",
"    ]. The entry criteria included clinical hypertension (sitting blood pressure 160 to",
"    <span class=\"nowrap\">",
"     200/95",
"    </span>",
"    to 115 mmHg) and left ventricular hypertrophy as determined by the electrocardiogram, not echocardiography, which can detect earlier stage disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this double-blind study, 9193 patients between the ages of 55 and 80 who fulfilled the entry criteria (mean blood pressure",
"    <span class=\"nowrap\">",
"     177/97",
"    </span>",
"    mmHg, which was much higher than in HOPE and EUROPA) were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    - or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    -based therapy, with dose increases and the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    (as well as other agents) to attain the target blood pressure levels (sitting systolic and diastolic pressures less than 140 and less than 90 mmHg, respectively). The initial and subsequent doses of both losartan and atenolol were 50 and 100",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    respectively. Baseline characteristics, particularly those relating to risk factors for cardiovascular outcomes, were similar in both groups.",
"   </p>",
"   <p>",
"    The primary end point was one of the following events: cardiovascular death, MI, or stroke, while the composite end point was any one of these primary events. The study was continued until at least 1040 patients had experienced a primary event (which was calculated to have provided sufficient study power), but not until the last enrolled patient had been followed for at least four years.",
"   </p>",
"   <p>",
"    Compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    was associated with a significantly decreased incidence of the primary composite end point (11 versus 13 percent, adjusted hazard ratio [AHR] 0.87, 95% CI 0.77-0.98) that was primarily due to a reduction in fatal or nonfatal stroke (5 versus 7 percent, AHR 0.75, 95% CI 0.63-0.89). This was principally due to a lower risk of atherothrombotic stroke, as noted by secondary analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/62\">",
"     62",
"    </a>",
"    ]. Since the fall in blood pressure was similar in the two groups",
"    <span class=\"nowrap\">",
"     (30/17",
"    </span>",
"    mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/55\">",
"     55",
"    </a>",
"    ], losartan seemed to have benefits beyond blood pressure reduction.",
"   </p>",
"   <p>",
"    A subsequent subgroup analysis found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    was not associated with decreased risk of the composite endpoint in lower risk patients (without previous cardiovascular disease, diabetes, or isolated systolic hypertension, and no or only mild left ventricular hypertrophy), but was associated with a significant reduction in the risk of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antihypertensive therapy was associated with regression of left ventricular hypertrophy in 77 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/64\">",
"     64",
"    </a>",
"    ]. The degree of regression, using ECG criteria, was approximately twice as large at one year with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/55\">",
"     55",
"    </a>",
"    ]; the relative benefit was greater in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/47/20218/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues pertaining to the choice of antihypertensive drugs in patients with diabetes mellitus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of different classes of antihypertensive drugs can be used for initial therapy of hypertension. These include the thiazide diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, calcium channel blockers, and beta blockers. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice among the different antihypertensive drugs is not made on the basis of efficacy. Each of the first-line drugs is roughly equally effective, producing a good antihypertensive response in 30 to 50 percent of cases, although there is substantial interpatient variability. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most antihypertensive drugs provide the same degree of cardiovascular protection, particularly cardiovascular morbidity and mortality, although there may be some differences in selected outcomes, such as stroke, or in noncardiovascular outcomes such as the development of diabetes. The amount of blood pressure reduction appears to be the major determinant of cardiovascular risk rather than the choice of antihypertensive drug. However, based upon the results of the ACCOMPLISH trial, this conclusion about equivalent efficacy of the different drugs may not apply to combination therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Does the choice of drug affect outcome?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies show that beta blockers do not offer the same degree of primary protection against stroke as other antihypertensive drugs in patients with essential hypertension who have no specific indications for their use (eg, resting tachycardia, angina pectoris, or a recent myocardial infarction). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Beta blockers as initial therapy?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/1\">",
"      Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/2\">",
"      Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/3\">",
"      Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/4\">",
"      Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/5\">",
"      Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/6\">",
"      Bidiville J, Nussberger J, Waeber G, et al. Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension 1988; 11:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/7\">",
"      Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med 1996; 101:22S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/8\">",
"      Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353:2008.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (NICE clinical guideline update). Available at: file://www.nice.org.uk. Accessed January 21, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/10\">",
"      Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/11\">",
"      Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/12\">",
"      Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/13\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/14\">",
"      Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/15\">",
"      MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985; 291:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/16\">",
"      Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992; 304:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/17\">",
"      Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/18\">",
"      Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/19\">",
"      Niskanen L, Hedner T, Hansson L, et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/20\">",
"      Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/21\">",
"      Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/22\">",
"      Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/23\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/24\">",
"      Davis BR, Cutler JA, Furberg CD, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med 2002; 137:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/25\">",
"      Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008; 168:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/26\">",
"      Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/27\">",
"      Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/28\">",
"      Davis BR, Piller LB, Cutler JA, et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006; 113:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/29\">",
"      Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/30\">",
"      Messerli FH, Weber MA. ALLHAT--all hit or all miss? Key questions still remain. Am J Cardiol 2003; 92:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/31\">",
"      McInnes GT. Size isn't everything--ALLHAT in perspective. J Hypertens 2003; 21:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/32\">",
"      Chrysant SG. The ALLHAT study: results and clinical implications. QJM 2003; 96:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/33\">",
"      Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/34\">",
"      Frohlich ED. Treating hypertension - what are we to believe? N Engl J Med 2003; 348:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/35\">",
"      Davis BR, Furberg CD, Wright JT Jr, et al. ALLHAT: setting the record straight. Ann Intern Med 2004; 141:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/36\">",
"      Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/37\">",
"      Bakris GL, Gaxiola E, Messerli FH, et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension 2004; 44:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/38\">",
"      Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/39\">",
"      Dahl&ouml;f B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/40\">",
"      Poulter NR, Wedel H, Dahl&ouml;f B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/41\">",
"      Poulter NR, Dobson JE, Sever PS, et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009; 54:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/42\">",
"      Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/43\">",
"      Chobanian AV. Clinical practice. Isolated systolic hypertension in the elderly. N Engl J Med 2007; 357:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/44\">",
"      Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/45\">",
"      ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/46\">",
"      Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/47\">",
"      Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/48\">",
"      Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/49\">",
"      Jamerson KA, Devereux R, Bakris GL, et al. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension 2011; 57:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/50\">",
"      Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 1991; 17:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/51\">",
"      Psaty BM, Koepsell TD, LoGerfo JP, et al. Beta-blockers and primary prevention of coronary heart disease in patients with high blood pressure. JAMA 1989; 261:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/52\">",
"      Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/53\">",
"      Furberg CD, Cutler JA. Diuretic agents versus beta-blockers. Comparison of effects on mortality, stroke, and coronary events. Hypertension 1989; 13:I57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/54\">",
"      Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986; 293:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/55\">",
"      Dahl&ouml;f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/56\">",
"      Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/57\">",
"      Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/58\">",
"      Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/59\">",
"      Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/60\">",
"      Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008; 117:2706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/61\">",
"      Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/62\">",
"      Kizer JR, Dahl&ouml;f B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005; 45:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/63\">",
"      Franklin SS, Wachtell K, Papademetriou V, et al. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension 2005; 46:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/64\">",
"      Wachtell K, Bella JN, Rokkedal J, et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002; 105:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/47/20218/abstract/65\">",
"      Lindholm LH, Ibsen H, Dahl&ouml;f B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3857 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20218=[""].join("\n");
var outline_f19_47_20218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DOES THE CHOICE OF DRUG AFFECT OUTCOME?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MRC trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CAPPP trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      STOP Hypertension 2 trial and NORDIL trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INSIGHT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ALLHAT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Summary of ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANBP2 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Summary of ANBP2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INVEST trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ASCOT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Summary of ASCOT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ONTARGET trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ACCOMPLISH trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Beta blockers as initial therapy?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Trials in specific subgroups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HYVET trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - High cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - LIFE trial of severe LVH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3857\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3857|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/22/38253\" title=\"figure 1\">",
"      Response to antihypertensives in blacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/36/2638\" title=\"figure 2\">",
"      Single drug in whites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7166\" title=\"figure 3\">",
"      AHT drug and outcome ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/59/40893\" title=\"figure 4\">",
"      AHT drug and HF ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/18/40237\" title=\"figure 5\">",
"      AHT drug and stroke ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/52/16206\" title=\"figure 6\">",
"      RR of HF amlo vs chlor ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/60/15310\" title=\"figure 7\">",
"      RR of CV lisin vs chlor ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/45/16094\" title=\"figure 8\">",
"      RR of HF lisin vs chlor ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/34/15918\" title=\"figure 9\">",
"      RR stroke lisin vs chlor ALLHAT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=related_link\">",
"      Evaluation of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=related_link\">",
"      Treatment of hypertension in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_47_20219="Antifungal treatments PI";
var content_f19_47_20219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Topical antifungal agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       How supplied",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Terbinafine (Lamisil&reg;)*",
"      </td>",
"      <td>",
"       Cream, gel",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clotrimazole (Lotrimin&reg;)*",
"      </td>",
"      <td>",
"       Cream, lotion, solution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Econazole (Spectazole&reg;)",
"      </td>",
"      <td>",
"       Cream",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sulconazole (Exelderm&reg;)",
"      </td>",
"      <td>",
"       Cream, solution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oxiconazole (Oxistat&reg;)",
"      </td>",
"      <td>",
"       Cream, lotion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Naftifine (Naftin&reg;)",
"      </td>",
"      <td>",
"       Cream, gel",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ciclopirox (Loprox&reg;)",
"      </td>",
"      <td>",
"       Cream, lotion, liquid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ketoconazole (Nizoral&reg;)",
"      </td>",
"      <td>",
"       Cream",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sertaconazole (Ertaczo&reg;)",
"      </td>",
"      <td>",
"       Cream",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Miconazole (Monistat&reg;)*",
"      </td>",
"      <td>",
"       Cream",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tolnaftate (Tinactin&reg;)*",
"      </td>",
"      <td>",
"       Cream, gel, powder, spray, liquid",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Available without a prescription.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20219=[""].join("\n");
var outline_f19_47_20219=null;
var title_f19_47_20220="Laser and light sources for treating leg veins";
var content_f19_47_20220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laser and light sources for treating leg veins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Wavelength, nm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vein diameter, mm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Skin type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nd:YAG",
"       </td>",
"       <td>",
"        1064",
"       </td>",
"       <td>",
"        0.3 to 3",
"       </td>",
"       <td>",
"        I,II,III,IV",
"       </td>",
"       <td>",
"        Pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PDL",
"       </td>",
"       <td>",
"        595",
"       </td>",
"       <td>",
"        &lt;1.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Bruising",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diode",
"       </td>",
"       <td>",
"        800 to 900",
"       </td>",
"       <td>",
"        to 4",
"       </td>",
"       <td>",
"        I,II,III,IV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KTP",
"       </td>",
"       <td>",
"        532",
"       </td>",
"       <td>",
"        0.5 to 1.0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Pigmentation changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alexandrite",
"       </td>",
"       <td>",
"        755",
"       </td>",
"       <td>",
"        &gt;0.4",
"       </td>",
"       <td>",
"        I,II,III",
"       </td>",
"       <td>",
"        Bruising, telangiectatic matting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IPLS*",
"       </td>",
"       <td>",
"        500 to 1000",
"       </td>",
"       <td>",
"        &lt;1 (red)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     Nd:YAG: Neodymium-doped yttrium aluminum garnet",
"     <br>",
"      PDL: Pulse dye laser",
"      <br>",
"       KTP: Potassium titanyl phosphate",
"       <br>",
"        IPLS: Intense pulsed light system",
"        <br>",
"         * Not a laser.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      Kunishige JH, Goldberg LH, Friedman PM. Laser therapy for leg veins. Clin Dermatol 2007; 25:454.",
"      <br>",
"       Eremia S, Li C, Umar SH. A side-by-side comparative study of 1064 nm Nd:YAG, 810 nm diode and 755 nm alexandrite lasers for treatment of 0.3-3 mm leg veins. Dermatol Surg 2002; 28:224.",
"       <br>",
"        Chen JZ, Alexiades-Armenakas MR, Bernstein LJ, et al. Two randomized, double-blind, placebo-controlled studies evaluating the S-Caine Peel for induction of local anesthesia before long-pulsed Nd:YAG laser therapy for leg veins. Dermatol Surg 2003; 29:1012.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20220=[""].join("\n");
var outline_f19_47_20220=null;
var title_f19_47_20221="Genetic mutations survival II";
var content_f19_47_20221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival in hypertrophic cardiomyopathy is related to the genetic defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 285px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival curves show that survival free of death or transplantation is better for patients with hypertrophic cardiomyopathy who have mutations of the cardiac myosin binding protein-C (MYBPC3) gene compared to those with mutations of the beta-cardiac myosin heavy chain gene (p&lt;0.0001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Charron, P, Dubourg, O, Desnos, M, et al, Circulation 1998; 97:2230.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20221=[""].join("\n");
var outline_f19_47_20221=null;
var title_f19_47_20222="Abduction exercise for frozen shoulder";
var content_f19_47_20222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abduction exercise for frozen shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To stretch the inferior portion of the shoulder capsule, the seated patient places their elbow and forearm on a table and gently abducts the shoulder by sliding the forearm away from their body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tore Prestgaard, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20222=[""].join("\n");
var outline_f19_47_20222=null;
var title_f19_47_20223="Bronchial obstruction";
var content_f19_47_20223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/62908/trachobs_conv.mp4?title=Bronchial+obstruction\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Central airway obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Video shows severe, bilateral bronchial obstruction and widening of the main carina due to growth of bronchogenic adenocarcinoma into the lower third of the trachea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henri G Colt, MD and Praveen Mathur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_47_20223=[""].join("\n");
var outline_f19_47_20223=null;
